17 alpha-hydroxyprogesterone caproate has been researched along with Pregnancy in 321 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 37 (11.53) | 18.7374 |
| 1990's | 7 (2.18) | 18.2507 |
| 2000's | 64 (19.94) | 29.6817 |
| 2010's | 163 (50.78) | 24.3611 |
| 2020's | 50 (15.58) | 2.80 |
| Authors | Studies |
|---|---|
| Alavi, A; Atighpoor, F; Ranjbar, A; Zare, S | 1 |
| Chomba, E; Cole, SR; Freeman, BL; Goldenberg, RL; Kasaro, MP; Mbewe, FM; Muyangwa, D; Mwape, H; Peterson, M; Phiri, WM; Price, JT; Rouse, DJ; Saha, PT; Sindano, N; Smithmyer, ME; Stringer, JSA; Vwalika, B | 1 |
| Bowman, ME; Herrera, CL; McIntire, DD; Nelson, DB; Smith, R | 1 |
| Cirillo, PM; Cohn, BA; Krigbaum, NY; Murphy, CC | 1 |
| Caritis, SN; Hauspurg, A; Megli, CJ; Venkataramanan, R | 1 |
| Boelig, RC; Garcia, SM; Kellom, KS; Matone, M; Wang, X | 1 |
| Donohue, JM; Dusetzina, SB; Gavulic, KA; Sachs, RE | 1 |
| Finneran, MM; Frey, HA; Hade, EM; Iams, JD; Landon, MB; Lynch, CD; Waickman, C | 1 |
| Backley, S; Berghella, V; Boelig, RC; Frey, H; Gimovsky, AC; Schoen, CN; Springel, E | 1 |
| Alizadeh, F; Mahmoudinia, M; Mirteimoori, M; Niroumand, S; Pourali, L | 1 |
| Biron-Shental, T; Cohen, G; Miller, N; Moran, R; Ovadia, M; Schreiber, H; Shavit, M; Shechter-Maor, G; Weitzner, O; Yagur, Y | 1 |
| Berghella, V; Boelig, RC; Gragnano, E; Locci, M; Saccone, G | 1 |
| Dresang, L; Vellardita, L | 1 |
| Beam, AL; Hakim, JB; Hart, JM; Wylie, BJ | 1 |
| Cole, SR; Conner, MG; Freeman, BL; Kasaro, MP; Mabula-Bwalya, CM; Price, JT; Sebastião, YV; Stringer, EM; Stringer, JSA; Vwalika, B | 1 |
| Boelig, RC | 1 |
| Badawy, ER; Mostafa, SA; Othman, MA; Shaltout, AS; Sobh, AMA | 1 |
| Blumenfeld, YJ; Datoc, IA; Druzin, ML; El-Sayed, YY; Girsen, AI; Kan, P; Leonard, SA; Shaw, GM; Stevenson, DK; Tsur, A | 1 |
| Heyborne, K | 1 |
| Adams Waldorf, KM; Baxter, C; Coler, B; Crary, I; Huebner, EM; Marcell, L; Rutz, S | 1 |
| Cerrillos, L; Fernandez-Macias, R; Figueras, F; Martinez-Portilla, RJ; Palacio, M | 1 |
| Baker, J; Biggio, JR; Birch, R; Blackwell, SC; Chauhan, SP; Das, AF; Duncan, M; Gudeman, J; Gyamfi-Bannerman, C; Hughes, BL; Jozwiakowski, MJ; Krop, J; Louis, JM; Manuck, TA; Miller, HS; Nielsen, P; Pekarev, O; Reznichenko, GI; Reznichenko, NY; Saade, GR; Tatarova, N; Williams, L; Yuzko, OM | 1 |
| Ali, MK; Attyia, KM; Shaamash, AH | 1 |
| Owen, J; Szychowski, JM; Williams, BN; Wood, SL | 1 |
| Rubin, R | 1 |
| Godlewski, BJ; Harrod, CS; King, VJ; Sobolik, LI | 1 |
| Serpa, RO; Wagner, CK; Wood, RI | 1 |
| Gandell, DL; Gudeman, JL; Randell, MD | 1 |
| Das, AF; Saade, GR; Sibai, B | 1 |
| Liu, LY; Miller, ES; Roy, A; Sakowicz, A; Yee, LM | 1 |
| Amaral, LM; Comley, KM; Cottrell, JN; Cunningham, MW; Ibrahim, T; LaMarca, B; Vaka, VR; Witcher, A | 1 |
| Leveno, KJ; McIntire, DD; Nelson, DB | 4 |
| Das, AF; Gudeman, J; Saade, GR; Sibai, B | 1 |
| Chang, CY; Guo, J; Joffe, HV; Johnson, LL; Nguyen, CP; Wesley, B | 1 |
| Greene, MF; Harrington, D; Klebanoff, MA | 1 |
| Caritis, SN; Combs, CA; Lemon, L; Megli, C; Venkataramanan, R | 1 |
| Al-Kouatly, HB; Berghella, V; Boelig, RC; Greenberg, V; Valcarcel, B; Ward, A | 1 |
| Babbar, S; Edwards, AM; Forinash, AB; Lowry, SA; Mikovich, S | 1 |
| Armbruster, R; Boerrigter, A; Childress, K; Franklin, BHK; Massa, K; Sauer, M; Tomlinson, T; Vricella, LK | 1 |
| Anders, NM; Bailey, A; Bensouda, S; Burd, I; DeLong, K; Dimitrion, P; Ensign, LM; Hanes, J; Laney, V; Li, G; Mahendroo, M; Mesiano, S; Ortiz, JI; Scardina, M; Wagner, G; Yu, J; Zierden, HC | 1 |
| Abdalla, A; Dotters-Katz, SK; Hynes, JS; Manuck, TA; Schwartz, AR | 1 |
| Ananth, CV; D'Alton, ME; Friedman, AM; Gomez, D; Gyamfi-Bannerman, C; Huang, Y; Schuster, M; Wright, JD | 1 |
| Carter, DM; DeLong, K; Ensign, LM; Shapiro, RL; Zierden, HC | 1 |
| Ajao, A; Chang, C; Cosgrove, A; Kolonoski, J; Moeny, D; Nguyen, CP; Shinde, M; Tsai, HT; Woods, CM | 1 |
| Rascati, KL; Zhang, S | 1 |
| Fujimori, K; Fukuda, T; Kyozuka, H; Murata, T; Yamaguchi, A; Yasuda, S | 1 |
| Lolier, M; Miller, RO; Wagner, CK; Wood, RI | 1 |
| Fahrenkopf, A; Li, G; Wagner, CK; Wood, RI | 1 |
| Eke, AC; Hesson, A; Oler, E | 1 |
| Owens, L; Prager, S | 1 |
| Bustos, ML; Caritis, SN; Carpenter, MW; Iams, JD; Jablonski, KA; Manuck, T; Mercer, BM; Peaceman, AM; Ramin, SM; Reddy, UM; Rouse, DJ; Sciscione, A; Sorokin, Y; Varner, MW; Wapner, RJ | 1 |
| Dotters-Katz, SK; Goodnight, WH; Manuck, TA; Ning, A; Vladutiu, CJ | 1 |
| Abramovici, AR; Biggio, JR; Harper, LM; Jauk, VC; Kuper, SG; Tita, AT | 1 |
| Grant, JH; Manuck, TA; Vladutiu, CJ | 1 |
| Acaia, B; Benedetto, C; Di Tommaso, M; DʼAmico, R; Facchinetti, F; Locatelli, A; Marozio, L; Pignatti, L; Spitaleri, M; Vergani, P; Vicini, R; Zaina, B | 1 |
| Anguiano, RH; Bobowski, C; Mastrogiannis, D; Milikhiker, N; Stone, RH | 1 |
| Apostolakis-Kyrus, K; Gomez, LM; Merriman, AL; Samson, FD; Tate, DL | 1 |
| O'Brien, JM | 6 |
| Fang, D; Garfield, RE; Kuon, R; Moreno, M; Xia, H | 1 |
| Greenwood, BC; Hydery, T; Jeffrey, PL; Kunte, PS; Lenz, K; Mauro, RP; Price, MK; Takeshita, M | 1 |
| Manuck, TA | 1 |
| Beam, AL; Fried, I; Kohane, IS; Palmer, NP | 1 |
| Kumar, D; Lockwood, CJ; Mansour, JM; Mercer, BM; Mesiano, S; Moore, JJ; Moore, RM; Schatz, F | 1 |
| Gee, RE; Karas, LO; Kuy, S | 1 |
| Ahmed, M; Caritis, SN; Chang, J; D'Alton, ME; Famy, AS; Haas, DM; Haneline, LA; Hankins, G; Harris, J; Hebert, M; Ren, Z; Simhan, H; Venkataramanan, R; Yorio, P | 1 |
| Dexter, S; Zelig, C | 1 |
| Fry, RC; Manuck, TA; Martin, EM; Smeester, L; Smith, C; Tomlinson, MS; Varner, MW | 1 |
| Caritis, SN; Hauspurg, A; Lemon, LS; Serra, AE; Sharma, S; Venkataramanan, R | 1 |
| Blumenfeld, YJ; El-Sayed, YY; Langen, ES; Lyell, DJ; Sherwin, K; Sit, A | 1 |
| Chauhan, SP; Easter, SR; Little, SE; Mendez-Figueroa, H; Robinson, JN | 1 |
| Bagga, R; Bansal, P; Kalra, J; Kumar, P; Shambhavi, S | 1 |
| Berghella, V; Di Sarno, R; Mokhtari, N; Parker, P; Quist-Nelson, J; Saccone, G | 1 |
| Frappaolo, A; Vadnais, M | 1 |
| Biggio, JR; Birch, R; Blackwell, SC; Chauhan, SP; Das, AF; Gyamfi-Bannerman, C; Hughes, BL; Jozwiakowski, MJ; Louis, JM; Manuck, T; Miller, HS | 1 |
| Kawasaki, Y; Kitajima, I; Makimoto, M; Niimi, H; Saito, S; Shiozaki, A; Tamura, K; Ueno, T; Yoneda, N; Yoneda, S; Yoshida, T; Yoshino, O | 1 |
| Mesiano, S; Weatherborn, M | 1 |
| Benatar, S; Cheeks, M; Courtot, B; Cross-Barnet, C; Hill, I; Johnston, E | 1 |
| Caritis, SN; Hauspurg, A; Lemon, L; Venkataramanan, R | 1 |
| Bennett, PR; Sykes, L | 1 |
| Bofill, JA; Collier, CH; Morrison, JC; Pearson, M; Shwayder, JM | 1 |
| Di Sarno, R; Raffone, A; Saccone, G | 1 |
| Eke, AC; Graham, EM; Sheffield, J | 2 |
| Jackson, J; Leziak, K; Miller, ES; Yee, LM | 1 |
| Beyene, J; Jarde, A; Lutsiv, O; McDonald, SD | 1 |
| Berhie, SH; Bryant, AS; Riley, LE | 1 |
| Urato, AC | 1 |
| Baker, DA; Demishev, M; Garry, DJ; Kocis, C; Peresleni, T; Persad, MD | 1 |
| DeNoble, A; Janko, M; Lantos, P; Swamy, G; Weaver, K; Wheeler, S; Wynn, C | 1 |
| DeNoble, AE; Swamy, GK; Weaver, KE; Wheeler, SM; Wynn, CE | 1 |
| Chomba, E; Cole, SR; Freeman, BL; Goldenberg, RL; Mbewe, FM; Mofenson, LM; Mulenga, HB; Price, JT; Rouse, DJ; Stringer, JSA; Vwalika, B; Winston, J | 1 |
| Kalata, M; Swarr, V; Teter, K; Wagner, L; Witzeman, K | 1 |
| Cahill, AG; Carter, EB; Macones, GA; Olsen, MA; Stout, MJ; Tuuli, MG | 1 |
| Byrns, MC | 1 |
| Deeks, ED; Hines, M; Lyseng-Williamson, KA | 1 |
| Durnwald, CP | 1 |
| Azimi, S; Bretelle, F; Capelle, M; Connan, L; Deruelle, P; Langer, B; Laurent, Y; Mantel, A; Perrotin, F; Porcher, R; Rozenberg, P; Senat, MV; Vayssière, C; Winer, N | 1 |
| Anton, L; Elovitz, MA; Maubert, M; Nold, C; Yellon, S | 1 |
| Driggers, RW; Istwan, N; Rhea, D; Singh, J; Timofeev, J | 1 |
| Fan-Havard, P; Franco, A; Prescott, GM; Schmouder, VM | 1 |
| Kiprono, LV; Lamarca, B; Martin, J; Moseley, J; Wallace, K | 1 |
| Bekedam, DJ; Bloemenkamp, KW; Bruinse, HW; Christiaens, GC; Kwee, A; Lim, AC; Mol, BW; Mulder, EJ; Versteegh, EM | 1 |
| Romero, R; Stanczyk, FZ | 1 |
| Ananth, CV; Brubaker, S; Fuchs, K; Gyamfi-Bannerman, C; Moni, S; Nhan-Chang, CL; Pessel, C; Vink, J; Zork, N | 1 |
| Caritis, SN; Carpenter, MW; Grobman, WA; Harper, M; Iams, JD; Klebanoff, MA; Mercer, BM; Ramin, S; Rouse, DJ; Sciscione, A; Sorokin, Y; Thom, E; Thorp, JM; Varner, MW; Venkataramanan, R; Wapner, RJ | 1 |
| Parobchak, N; Roche, N; Rosen, M; Rosen, T; Wang, B | 1 |
| Iams, JD; Lynch, CD; Markham, KB; Walker, H | 1 |
| Briery, CM; Chauhan, SP; Klauser, CK; Magann, EF; Martin, RW; Morrison, JC | 1 |
| Combs, CA; Das, A; Garite, TJ; Maurel, K | 1 |
| Esplin, MS; Jackson, GM; Jorde, L; Manuck, TA; Moore, B; Varner, MW; Watkins, WS; Yandell, M | 1 |
| Haram, K; Morrison, JC; Mortensen, JH | 1 |
| Berghella, V; Gimovsky, A | 1 |
| Aboulghar, MA; Aboulghar, MM; Amin, YM; Awwad, J; Briery, CM; Cam, C; Caritis, SN; Çetingöz, E; Combs, CA; Fonseca, EB; Garite, T; Groenwold, RH; Karateke, A; Kwee, A; Lim, AC; Magann, EF; Maurel, K; Meseguer, J; Mol, BW; Moons, KG; Morrison, JC; Nassar, AH; Nicolaides, KH; Norman, JE; Perales, A; Rode, L; Ross, S; Rouse, DJ; Schuit, E; Serra, V; Stock, S; Tabor, A; Thom, EA; Usta, IM; Vayssiere, C; Wood, S; Worda, K; Zuithoff, NP | 1 |
| Awwad, J; Ghazeeri, G; Hayek, S; Nassar, AH; Saasouh, W; Succar, J; Usta, IM; Yacoub, N | 1 |
| Caritis, S; Feghali, M; Venkataramanan, R | 1 |
| Conde-Agudelo, A; Romero, R | 1 |
| Amaral, LM; Cornelius, DC; Harmon, A; LaMarca, B; Martin, JN; Moseley, J | 1 |
| Egerman, R; Istwan, N; Ramsey, R; Rhea, D; Stanziano, G | 1 |
| Azimi, S; Bohec, C; Bretelle, F; Capelle, M; Connan, L; Deruelle, P; Langer, B; Perrotin, F; Porcher, R; Rozenberg, P; Senat, MV; Vayssière, C; Winer, N | 1 |
| Berghella, V; Caughey, AB; Iams, JD; Schoen, CN; Tabbah, S | 1 |
| Berghella, V; Saccone, G; Suhag, A | 1 |
| Block-Abraham, D; Gee, RE; Orsulak, MK | 1 |
| Allen, TK; Buhimschi, IA; Feng, L; Grotegut, CA; Murtha, AP; Nazzal, M | 1 |
| Co, AL; Hade, EM; Iams, JD; Walker, HC | 1 |
| Abril, D; Clewell, W; Combs, CA; Das, A; Garite, TJ; Heyborne, K; How, H; Huang, W; Lewis, D; Lu, G; Maurel, K; Miller, H; Nageotte, M; Porreco, R; Sheikh, A; Tran, L | 1 |
| Owen, J; Subramaniam, A; Wetta, LL | 1 |
| Hughes, BL; Lopes, V; Mainiero, AD; Rouse, DJ | 1 |
| Chaemsaithong, P; Furcron, AE; Gomez-Lopez, N; Hassan, SS; Mahajan, A; Plazyo, O; Romero, R; Unkel, R; Xu, Y | 1 |
| Allshouse, AA; Carey, JC; Heyborne, KD | 1 |
| Ananth, CV; Hanna, N; Keeler, SM; Kiefer, DG; Peltier, MR; Rust, O; Vintzileos, AM | 1 |
| Lewis, DF; O'Brien, JM | 1 |
| Caritis, SN; Combs, CA; Garite, TJ; Lim, AC; Maurel, K; Mol, B; Rouse, D; Schuit, E; Thom, E; Tita, AT | 1 |
| Abdul Karim, AK; Lim, PS; Ng, BK; Ng, KS; Omar, MH; Shafiee, MN | 1 |
| Andrews, W; Biggio, J; Bukowski, R; Esplin, MS; Huang, H; Ilekis, J; Manuck, TA; Parry, S; Reddy, UM; Saade, G; Sadovsky, Y; Varner, MW; Zhang, H | 1 |
| Goodnight, W | 1 |
| Manuck, T; Menard, MK; Ollendorff, A; Stringer, EM; Stringer, JS; Verbiest, S; Vladutiu, CJ | 1 |
| Bolden, JR; Liu, LY; Miller, ES; Sakowicz, A; Yee, LM | 1 |
| Owen, J; Wood, SL | 1 |
| Caritis, SN; Feghali, MN; Grobman, WA; Rouse, DJ | 1 |
| Ahn, KH; Bae, NY; Cho, GJ; Hong, SC; Jee, HJ; Kim, HJ; Lee, EH; Lee, JS; Oh, MJ | 1 |
| Caritis, S; Hankins, G; Hebert, MF; Mattison, D; Miodovnik, M; Sharma, S; Venkataramanan, R | 1 |
| Elimian, A; Escobedo, MB; Goodman, JR; Knudtson, E; Smith, K; Williams, M | 1 |
| Esplin, MS; Fry, RC; Manuck, TA; Stoddard, GJ; Varner, MW | 1 |
| Allshouse, AA; Heyborne, KD | 1 |
| Bahrami, E; Bahrami, MA; Berghella, V; Chaman-Ara, K; Elimian, A; Khalifeh, A; Saccone, G | 1 |
| Heyborne, KD | 1 |
| Hibbard, JU; Leftwich, H; Stetson, B; Wilkins, I | 1 |
| Bayesh, S; Esmailzadeh, A; Heidari, R; Pirjani, R; Rahimi-Foroushani, A | 1 |
| Batra, P; Menard, MK; Stringer, EM; Stringer, JSA; Vladutiu, CJ | 1 |
| Haidar, ZA; Hosseini Nasab, S; Moussa, HN; Sibai, BM | 1 |
| Batra, P; Hirai, A; Lee, V; Lu, M; Selk, S | 1 |
| Andrews, W; Biggio, J; Bukowski, R; Esplin, MS; Huang, H; Ilekis, J; Jorde, LB; Manuck, TA; Parry, S; Reddy, UM; Saade, G; Sadovsky, Y; Varner, MW; Watkins, WS; Yandell, M; Zhan, H | 1 |
| Gard, J; Leveno, KJ; McDonald, J; McIntire, DD; Nelson, DB; Turrichi, P | 1 |
| Ahmed, MS; Hankins, GD; Hemauer, SJ; Mattison, DR; Nanovskaya, TN; Patrikeeva, SL; Yan, R | 1 |
| Dante, G; Facchinetti, F; Paganelli, S; Venturini, P; Volpe, A | 1 |
| Barhan, S; Desch, C; Duke, J; Istwan, N; Po, W; Rhea, D; Stanziano, G; Ventolini, G | 1 |
| Istwan, N; Newman, R; Rhea, D; Rittenberg, C; Stanziano, G; Sullivan, S | 2 |
| Caritis, S; Mada, SR; Mattison, D; Sharma, S; Torch, M; Venkataramanan, R; Zhang, S | 1 |
| Calda, P | 1 |
| Dadarwal, D; Dhaliwal, GS; Honparkhe, M; Kumar, A; Singh, J | 1 |
| Anderson, G; Caritis, SN; Carpenter, M; Harper, M; Iams, JD; Lo, J; Mercer, BM; Momirova, V; Peaceman, AM; Ramin, S; Rouse, DJ; Sciscione, A; Sorokin, Y; Spong, CY; Thorp, J; Varner, M; Wapner, RJ | 1 |
| Bornstein, E; Keeler, SM; Proudfit, CL | 1 |
| Keeler, SM; Kiefer, D; Novetsky, AP; Quinones, JN; Rochon, M; Rust, O | 1 |
| Catalano, PM; Mercer, BM; Schultz, BAH; Waters, TP | 1 |
| Barton, JR; Ho, SJ; Istwan, NB; O'Brien, JM; Rhea, DJ; Stanziano, GJ | 1 |
| Briery, CM; Chauhan, SP; Klauser, CK; Magann, EF; Martin, RW; Morrison, JC; Veillon, EW | 1 |
| Caritis, SN; Carpenter, MW; Conway, D; Dombrowski, M; Gyamfi, C; Horton, AL; Iams, JD; Lo, J; Meis, PJ; Mercer, BM; Miodovnik, M; Momirova, V; O'Sullivan, MJ; Peaceman, AM; Ramin, SM; Rouse, DJ; Sciscione, A; Sibai, B; Spong, CY; Varner, MW | 1 |
| Bennett, W; Cockrell, K; Granger, JP; Keiser, SD; LaMarca, B; Martin, JN; Parrish, MR; Ray, LF; Veillon, EW | 1 |
| Facchinetti, F; Vaccaro, V | 1 |
| Foglia, LM; Hill, DL; Hoeldtke, NJ; Napolitano, PG; Paonessa, DJ; Zelig, CM | 1 |
| Anderson, GD; Caritis, SN; Carpenter, MW; Harper, M; Iams, JD; Klebanoff, MA; Mercer, BM; Peaceman, AM; Ramin, SM; Rouse, DJ; Sciscione, A; Sorokin, Y; Thom, E; Thorp, J; Varner, MW; Wapner, RJ | 1 |
| Caritis, SN; Dorko, K; Ellis, EC; Mattison, DR; Sharma, S; Strom, SC; Venkataramanan, R; Zhang, S | 1 |
| Fox, NS; Istwan, NB; Klauser, CK; Rebarber, A; Rhea, DJ; Saltzman, DH; Stanziano, GJ | 1 |
| Blitz, M; Brower, M; Felix, JC; Goodwin, TM; Lee, RH; Li, A; Minoo, P; Patel, S | 1 |
| Berghella, V; Figueroa, D; Guzman, ER; Hankins, GD; Iams, JD; Owen, J; Perez-Delboy, A; Sheffield, JS; Szychowski, JM; Wing, DA | 1 |
| Caritis, SN; Carpenter, MW; Durnwald, CP; Harper, M; Lo, J; Malone, FD; Mercer, BM; Momirova, V; Peaceman, AM; Ramin, SM; Rouse, DJ; Sciscione, A; Sorokin, Y; Spong, CY; Thorp, JM; Varner, MW | 1 |
| Facchinetti, F | 1 |
| House, KM; Krueger, CR; Lucas, B; Mason, MV; Poole-Yaeger, A | 1 |
| Foglia, LM; Ippolito, DL; Napolitano, PG; Stallings, JD; Zelig, CM | 1 |
| Combs, CA; Das, A; Garite, T; Maurel, K; Porto, M | 1 |
| Berghella, V; Mackeen, AD; Rafael, TJ | 1 |
| Chawanpaiboon, S; Pimol, K; Sirisomboon, R | 1 |
| Armstrong, J | 2 |
| Cunningham, FG; Silver, RM | 1 |
| Cohen, AW; Copel, JA; Macones, GA; Menard, MK; Riley, L; Saade, GR | 1 |
| Adamczak, JE; Bastek, JA; Elovitz, MA; Hoffman, S; Srinivas, SK | 1 |
| Khadem, N; Mohajeri, T; Saghafi, N; Shakeri, MT | 1 |
| Hall, NR | 1 |
| Caritis, SN; Dombrowski, MP; Durnwald, CP; Lai, Y; Manuck, TA; Meis, PJ; Mercer, BM; Ramin, SM; Rouse, DJ; Sibai, B; Spong, CY; Wapner, RJ | 1 |
| Caritis, SN; Carpenter, M; Harper, M; Iams, JD; Lo, J; Malone, FD; Mercer, BM; Peaceman, AM; Ramin, S; Rouse, DJ; Sciscione, A; Sharma, S; Sorokin, Y; Spong, CY; Thorp, JM; Varner, MW; Venkataramanan, R | 1 |
| Dearmond, C; Henderson, ZT; How, H; Sibai, B; Wolfe, K | 1 |
| Chin, JR; Heine, RP; Murtha, AP; Ransom, CE; Roeder, HA; Sinclair, TR | 1 |
| King, AS; Omar, SZ; Tan, PC; Vallikkannu, N | 1 |
| Alexander, J; Coleman, S; Istwan, N; Wallace, L | 1 |
| Bernardus, RE; Bloemenkamp, K; Bruinse, HW; Duvekot, JJ; Erwich, JJHM; Groenwold, RHH; Hasaart, THM; Hummel, P; Kars, MM; Kwee, A; Lim, AC; Mol, BWJ; Papatsonis, D; Porath, MM; Schuit, E; Spaanderman, ME; van Eyck, J; van Oirschot, CM; van Pampus, MG; Willekes, C; Wilpshaar, J | 1 |
| Barton, JR; Barton, LA; Desch, CN; Istwan, NB; Rhea, DJ; Sibai, BM | 1 |
| Cordova, YC; Desch, CN; Gonzalez-Quintero, VH; Istwan, NB; Marimon, A; Rhea, DJ; Romary, LM; Stanziano, GJ; Tudela, F | 1 |
| Klinger, G; Merlob, P; Stahl, B | 1 |
| Ahmed, MS; Fokina, VM; Hankins, GD; Nanovskaya, TN; Zharikova, OL | 1 |
| Gupta, S; Roman, AS | 1 |
| Debieve, F; Hubinont, C | 1 |
| Bandino, JP; Hivnor, CM; Kennedy, JS; Thoppil, J | 1 |
| Chollet, JL; Jozwiakowski, MJ | 1 |
| Azimi, S; Azria, E; Bohec, C; Capelle, M; Chauveaud, A; Connan, L; Deruelle, P; Desbrière, R; Langer, B; Mantel, A; Perrotin, F; Porcher, R; Rozenberg, P; Vayssière, C; Winer, N | 1 |
| Istwan, N; Lucas, B; Mason, M; Poole-Yaeger, A; Rhea, D; Stanziano, G | 1 |
| Kuehn, BM | 1 |
| Birch, R; Hesley, R; Schardein, JL; Thorsrud, BA | 1 |
| Istwan, NB; Palmer, B; Sibai, BM; Stanziano, GJ | 1 |
| Fox, NS; Peress, D; Rebarber, A; Romero, J; Saltzman, DH; Schwartz, R | 1 |
| Berghella, V; Guzman, ER; Hankins, G; Iams, JD; Owen, J; Perez-Delboy, A; Sheffield, JS; Szychowski, JM; Wing, DA | 1 |
| Alfirevic, Z; Mujezinovic, F | 1 |
| Caritis, SN; Carpenter, M; Harper, M; Iams, JD; Lo, J; Malone, FD; Mercer, BM; Peaceman, AM; Ramin, SM; Rouse, DJ; Sciscione, A; Simhan, HN; Sorokin, Y; Spong, CY; Thorp, JM; Varner, MW; Zhao, Y | 1 |
| Benedetti, T; Caritis, SN; Fischer, D; Hankins, GD; Hebert, MF; Jackson, A; Mattison, D; Miodovnik, M; Sharma, S; Umans, JG; Venkataramanan, R; Zajicek, A | 1 |
| Bruinse, HW; de Graaf, IM; Hasaart, TH; Hummel, P; Kleiverda, G; Lim, AC; Mol, BW; Papatsonis, D; Porath, MM; Schuit, E; van Eyck, J; van Ginkel, AA; van Oirschot, CM | 1 |
| Blackwell, S; Caritis, SN; Esplin, MS; Grobman, WA; Iams, JD; Leveno, KJ; Mercer, BM; Rouse, DJ; Saade, GR; Sorokin, Y; Spong, CY; Thom, EA; Thorp, JM; Tita, AT; Tolosa, JE; Van Dorsten, JP; Wapner, RJ | 1 |
| Boyle, A; Driggers, RW; Feghali, M; Istwan, N; Rhea, D; Timofeev, J | 1 |
| Isoherranen, N; Thummel, KE | 1 |
| Berghella, V; Mackeen, AD; Rafael, TJ; Zavodnick, J | 1 |
| Caritis, SN; Carpenter, M; Conway, D; Dombrowski, MP; Gabbe, S; Hauth, JC; Iams, JD; Klebanoff, M; Leveno, KJ; Meis, PJ; Mercer, B; Miodovnik, M; Moawad, AH; O'Sullivan, MJ; Peaceman, AM; Ramin, SM; Sibai, B; Spong, CY; Thom, E; Thorp, JM; Varner, MW; Wapner, RJ | 1 |
| Greene, MF | 1 |
| Abendstein, BJ; Klingler, A; Kreuzer, E; Rjosk, HK; Schwärzler, P | 1 |
| Brancazio, LR; Heine, RP; Murtha, AP | 1 |
| TYLER, ET | 1 |
| JUNKMANN, K; SUCHOWSKY, G | 1 |
| SMITHBERG, M | 1 |
| REIFENSTEIN, EC | 1 |
| EICHNER, E | 1 |
| GILLESPIE, L; SEXTON, LI; WHITE, P | 1 |
| LUPU, CI; PLOTZ, EJ; WIENER, M | 1 |
| MATSUURA, S; OMICHI, J; UEDA, Y | 1 |
| BROWN, WH; CIOFFI, LA; MEYERHOFF, KH | 1 |
| GARRETT, WJ; SHEARMAN, RP | 1 |
| DECECCO, C; LOJODICE, G; VENTO, R | 1 |
| Doggrell, SA | 1 |
| Secher, NJ; Skajaa, K | 1 |
| Pushpalatha, T; Ramachandra Reddy, P; Sreenivasula Reddy, P | 1 |
| Baldini, D; Casini, ML; Costabile, L; Di Renzo, GC; Gerli, S; Unfer, V | 1 |
| Aslan, K; Bicakci, S; Bozdemir, H; Demirkiran, M; Ozeren, A | 1 |
| Friel, AM; Morrison, JJ; O'Reilly, MW; Sexton, DJ | 1 |
| Callaghan, WM; Damus, K; Green, NS; Howse, JL; Klebanoff, M; Lackritz, EM; Petrini, JR; Schwarz, RH | 1 |
| Delke, I; Kaunitz, AM; Sanchez-Ramos, L | 1 |
| Pushpalatha, T; Reddy, PR; Reddy, PS | 1 |
| Caritis, SN; Carpenter, M; Conway, D; Dombrowski, MP; Gabbe, S; Iams, JD; Klebanoff, M; Leindecker, S; Leveno, KJ; Meis, PJ; Mercer, B; Miodovnik, M; Moawad, AH; Northen, A; O'Sullivan, MJ; Peaceman, AM; Ramin, SM; Sibai, BM; Thorp, JM; Varner, MW; Wapner, RJ | 1 |
| Schindler, AE | 1 |
| el-Kabarity, H; Fawzy, MM; Sammour, MB; Schindler, AE | 1 |
| Fitzgerald, DR; Fuest, CM; House, KM; Inglis, JA; Kitson, BJ; Mason, MV | 1 |
| Amory, J; Lawler, R; Shields, L | 1 |
| Deering, SH; Gotkin, JL; Hoeldtke, NJ; Howard, BC; Napolitano, PG; Paonessa, DJ; Shields, AD | 1 |
| Macones, GA; Odibo, AO; Polsky, D; Stamilio, DM | 1 |
| Elovitz, MA; Mrinalini, C | 1 |
| Czeizel, AE; Dudás, I; Gidai, J | 1 |
| Loi, K; Tan, KT | 1 |
| Bailit, JL; Votruba, ME | 1 |
| Ferrara, LA; Hanley, ML; Istwan, NB; Rebarber, A; Rhea, DJ; Saltzman, DH; Stanziano, GJ | 1 |
| González-Quintero, VH; Hoffman, MC; Istwan, NB; Rhea, DJ; Smarkusky, L; Stanziano, GJ | 1 |
| Anderson, BL; Nau, GJ; Simhan, HN | 1 |
| Bloemenkamp, KW; Boer, K; Bruinse, HW; Duvekot, JJ; Erwich, JJ; Hasaart, TH; Hummel, P; Lim, AC; Mol, BW; Offermans, JP; Santema, JG; Scheepers, HC; Schöls, WA; van Oirschot, CM; Vandenbussche, FP; Wouters, MG | 1 |
| Abu-Musa, A; Hajami, F; Hannoun, A; Nassar, A; Usta, I | 1 |
| Anderson, G; Caritis, SN; Carpenter, M; Harper, M; Iams, JD; Lo, J; Malone, F; Mercer, BM; Peaceman, AM; Ramin, S; Rouse, DJ; Sciscione, A; Sorokin, Y; Spong, CY; Thom, EA; Thorp, J; Varner, M | 1 |
| Thornton, JG | 1 |
| Klebanoff, MA | 1 |
| Barton, JR; How, HY; Istwan, NB; Rhea, DJ; Stanziano, GJ | 1 |
| Cypher, R | 1 |
| Anderson, GD; Anderson, K; Bousleiman, S; Cotroneo, M; Divito, M; Dorman, K; Johnson, F; Kerr, M; Mallett, G; Milluzzi, C; Moseley, L; Norman, GS; Northen, AT; Pagliaro, S; Swain, M; Thom, E; Tillinghast, JA | 1 |
| Ahmed, MS; Fokina, V; Hankins, GD; Nanovskaya, TN; Yan, R | 1 |
| Attardi, BJ; Caritis, SN; Chiao, JP; Mattison, DR; Simhan, H; Zeleznik, A | 1 |
| Cleary-Goldman, J; Desch, C; Istwan, NB; Rebarber, A; Rhea, DJ; Russo-Stieglitz, K; Saltzman, DH | 1 |
| Caritis, SN; Carpenter, M; Conway, D; Dombrowski, MP; Iams, JD; Klebanoff, MA; Leveno, KJ; Meis, PJ; Mercer, BM; Miodovnik, M; Moawad, AH; Northen, A; O'Sullivan, MJ; Peaceman, AM; Ramin, SM; Sibai, BM; Thorp, JM; Varner, MW; Wapner, RJ; Zhao, Y | 1 |
| Gerhard, I; Runnebaum, B | 1 |
| Behrman, SJ | 1 |
| Morsman, J; Varma, TR | 1 |
| Cameron, AH; Gornall, P; Mann, JR; Rayner, PH; Shah, KJ | 1 |
| Kester, PA | 1 |
| Johnson, CK; Nelson, GW; Seegmiller, RE | 1 |
| Brekken, AL; Gilstrap, LC; Hauth, JC; Hauth, JM | 1 |
| Einen, MA; Osman, M; Sibaie, F; Souka, AR | 1 |
| Creasy, RK; Herron, MA | 1 |
| Myśkow, M; Szubert, D | 1 |
| Pulkkinen, MO | 1 |
| Heinze, A; Schlegel, W | 1 |
| Hühn, U; Lutter, K | 1 |
| Hartikainen-Sorri, AL; Jänne, O; Järvinen, PA; Kauppila, A; Tuimala, R | 1 |
| Hartikainen-Sorri, AL; Kauppila, A; Tuimala, R | 1 |
| Kawabe, N; Minoura, H; Nakashima, K; Sugiyama, T; Tanaka, M | 1 |
| Hyland, JH; McKinnon, AO; Nobelius, AM; Tarrida del Marmol Figueroa, S; Vasey, JR | 1 |
| Abate, A; Abate, FG; Balzano, E; Brigandì, A; Costabile, L; Perino, M | 1 |
| Bildirici, I; Bukulmez, O; Gurgan, T; Yarali, H; Yucel, A | 1 |
| Costabile, L; Di Renzo, GC; Gerli, S; Manna, C; Rossetti, D; Unfer, V | 1 |
| Charkviani, L; Charkviani, T; Kobiashvili, H | 1 |
| Abendstein, BJ; Kreuzer, E; Rjosk, HK; Schwärzler, P | 1 |
| Diedrich, K; Krebs, D; Luckhaus, J; Prietl, G; van der Ven, HH | 1 |
| Spätling, L | 1 |
| Keirse, MJ | 1 |
| Bokhman, IaV; Chepik, OF; Vishnevskiĭ, AS; Volkova, AT | 1 |
| Crain, JL; East, JM; Rosenberg, SM; Wood, SC | 1 |
| Ashkenazy, M; Czernobilsky, B; Kessler, I; Lancet, M; Nahshoni, A | 1 |
| Doesburg, WH; Eskes, TK; Reijnders, FJ; Rolland, R; Thomas, CM | 1 |
| Anderson, DC; Cantrill, J; Mamtora, H; Mavroudis, K; Newman, M; Petsos, P; Ratcliffe, WA; Shingles, C; Zulkifli, Z | 1 |
| Ashkenazi, J; Ben-David, M; Dicker, D; Feldberg, D; Goldman, JA; Voliovitz, I | 1 |
| Binkerd, P; Günzel, P; Hendrickx, AG; Korte, R; Leuschner, F; Neumann, BW; Poggel, A; Prahalada, S | 1 |
| Hochner-Celnikier, D; Iohan, F; Marandici, A; Monder, C | 1 |
| Suvonnakote, T | 1 |
| Jessup, D; Leeton, J; Trounson, A | 1 |
| Bruen, JA; Hick, JF; Kurland, LT; Noller, KL; O'Fallon, WM; Resseguie, LJ | 1 |
| Noda, K; Shinyashiki, K; Yoshida, T | 1 |
45 review(s) available for 17 alpha-hydroxyprogesterone caproate and Pregnancy
| Article | Year |
|---|---|
Vaginal progesterone compared with intramuscular 17-alpha-hydroxyprogesterone caproate for prevention of recurrent preterm birth in singleton gestations: a systematic review and meta-analysis.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Caproates; Female; Humans; Infant, Newborn; Pregnancy; Premature Birth; Progesterone; Progestins; Randomized Controlled Trials as Topic | 2022 |
Obstetric Indications for Progestin Therapy.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Premature Birth; Progesterone; Progestins | 2023 |
Reassessing Preterm Birth Prevention After the Withdrawal of 17-α Hydroxyprogesterone Caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Female; Humans; Infant, Newborn; Pregnancy; Premature Birth; Progesterone | 2023 |
A systematic review and meta-analysis of randomized controlled trials comparing 17-alpha-hydroxyprogesterone caproate versus placebo for the prevention of recurrent preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Humans; Infant, Newborn; Perinatal Death; Pregnancy; Pregnancy Trimester, Second; Premature Birth; Randomized Controlled Trials as Topic | 2019 |
Safety review of hydroxyprogesterone caproate in women with a history of spontaneous preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abortion, Spontaneous; Female; Humans; Infant, Newborn; Pregnancy; Premature Birth; Stillbirth; United States; United States Food and Drug Administration | 2021 |
Next generation strategies for preventing preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Animals; Drug Approval; Drug Development; Female; Humans; Infant, Newborn; Pregnancy; Premature Birth; Progestins; Risk Factors | 2021 |
Meta-analysis of randomized controlled trials comparing 17α-hydroxyprogesterone caproate and vaginal progesterone for the prevention of recurrent spontaneous preterm delivery.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Female; Humans; Hydroxyprogesterones; Injections, Intramuscular; Pregnancy; Premature Birth; Progesterone; Progestins; Randomized Controlled Trials as Topic; Recurrence | 2017 |
17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Evidence-Based Medicine; Female; Gestational Age; Humans; Hydroxyprogesterones; Obstetrics; Pregnancy; Premature Birth; Progestins; Recurrence; Risk Assessment; Risk Factors; United States | 2017 |
Progestogens in singleton gestations with preterm prelabor rupture of membranes: a systematic review and metaanalysis of randomized controlled trials.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Fetal Membranes, Premature Rupture; Humans; Pregnancy; Premature Birth; Progestins; Randomized Controlled Trials as Topic; Time Factors | 2018 |
Rationale for current and future progestin-based therapies to prevent preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Cervical Length Measurement; Clinical Trials as Topic; Female; Humans; Injections, Intramuscular; Pituitary Gland; Pregnancy; Premature Birth; Progestins; Uterus | 2018 |
Efficacy of progesterone for prevention of preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Clinical Trials as Topic; Female; Humans; Labor, Obstetric; Pregnancy; Pregnancy Outcome; Premature Birth; Progestins | 2018 |
Effects of progestogens in women with preterm premature rupture of membranes.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Fetal Membranes, Premature Rupture; Gestational Age; Humans; Infant, Newborn; Pregnancy; Pregnancy Outcome; Premature Birth; Progesterone; Progestins; Randomized Controlled Trials as Topic | 2019 |
Adjuvant 17-hydroxyprogesterone caproate in women with history-indicated cerclage: A systematic review and meta-analysis.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Cerclage, Cervical; Combined Modality Therapy; Estrogen Antagonists; Female; Humans; Pregnancy; Premature Birth; Secondary Prevention | 2019 |
Vaginal progesterone, oral progesterone, 17-OHPC, cerclage, and pessary for preventing preterm birth in at-risk singleton pregnancies: an updated systematic review and network meta-analysis.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Administration, Oral; Cerclage, Cervical; Cervical Length Measurement; Cervix Uteri; Female; Humans; Infant, Newborn; Network Meta-Analysis; Perinatal Death; Pessaries; Pregnancy; Pregnancy, High-Risk; Premature Birth; Progesterone; Randomized Controlled Trials as Topic; Treatment Outcome | 2019 |
17α-Hydroxyprogesterone Caproate and the Risk of Glucose Intolerance in Pregnancy: A Systematic Review and Meta-analysis.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Diabetes, Gestational; Female; Glucose Intolerance; Humans; Pregnancy; Premature Birth; Progestins | 2019 |
Regulation of progesterone signaling during pregnancy: implications for the use of progestins for the prevention of preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Animals; Female; Gene Expression Regulation; Humans; Hydroxyprogesterones; Metabolic Networks and Pathways; Molecular Targeted Therapy; Pregnancy; Premature Birth; Progesterone; Progestins; Receptors, Progesterone; Signal Transduction | 2014 |
The rebirth of progesterone in the prevention of preterm labor.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Obstetric Labor, Premature; Pregnancy; Premature Birth; Progesterone; Randomized Controlled Trials as Topic | 2013 |
Progesterone is not the same as 17α-hydroxyprogesterone caproate: implications for obstetrical practice.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Animals; Female; Humans; Hydroxyprogesterones; Mice; Obstetrics; Pregnancy; Premature Birth; Progesterone; Progestins; Terminology as Topic | 2013 |
Cerclage, progesterone and α-hydroxyprogeterone caproate treatment in women at risk for preterm delivery.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Cerclage, Cervical; Female; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth; Progestins | 2014 |
Effectiveness of progestogens to improve perinatal outcome in twin pregnancies: an individual participant data meta-analysis.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Adult; Bronchopulmonary Dysplasia; Cerebral Hemorrhage; Cervical Length Measurement; Cervix Uteri; Enterocolitis, Necrotizing; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Infant, Newborn, Diseases; Perinatal Death; Pregnancy; Pregnancy, Twin; Premature Birth; Progesterone; Progestins; Respiratory Distress Syndrome, Newborn; Treatment Outcome | 2015 |
Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Obstetric Labor, Premature; Pregnancy; Premature Birth; Progestins | 2014 |
17-alpha-hydroxyprogesterone caproate for maintenance tocolysis: a systematic review and metaanalysis of randomized trials.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy Trimester, Third; Progesterone Congeners; Publication Bias; Randomized Controlled Trials as Topic | 2015 |
Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth; Progesterone; Progestins | 2016 |
17-Hydroxyprogesterone caproate in triplet pregnancy: an individual patient data meta-analysis.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy, Triplet; Premature Birth; Progestins; Treatment Outcome | 2016 |
Clinical Application of Progesterone for the Prevention of Preterm Birth, 2016.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Cervix Uteri; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Injections, Intramuscular; Pregnancy; Pregnancy, Twin; Premature Birth; Progesterone; Recurrence; United States | 2016 |
Vaginal Cerclage: Preoperative, Intraoperative, and Postoperative Management.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Amniocentesis; Anti-Bacterial Agents; Anti-Infective Agents, Local; Cerclage, Cervical; Cervical Length Measurement; Device Removal; Directive Counseling; Female; Fetal Membranes, Premature Rupture; Humans; Hydroxyprogesterones; Perioperative Care; Physical Examination; Pregnancy; Premature Birth; Prolapse; Secondary Prevention; Suture Techniques; Sutures; Uterine Cervical Incompetence | 2016 |
What we have learned about the role of 17-alpha-hydroxyprogesterone caproate in the prevention of preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cervical Length Measurement; Cervix Uteri; Estrogen Antagonists; Evidence-Based Medicine; Female; Gestational Age; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Pregnancy, Multiple; Premature Birth; Progesterone; Progestins; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome | 2016 |
The safety of progestogen in the prevention of preterm birth: meta-analysis of neonatal mortality.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Female; Humans; Hydroxyprogesterones; Infant; Infant Mortality; Infant, Newborn; Injections, Intramuscular; Pregnancy; Pregnancy, Multiple; Premature Birth; Progesterone; Progestins | 2017 |
Vaginal progesterone vs intramuscular 17α-hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth in singleton gestations: systematic review and meta-analysis of randomized controlled trials.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Drug Administration Schedule; Female; Humans; Hydroxyprogesterones; Injections, Intramuscular; Intensive Care Units; Patient Admission; Pregnancy; Premature Birth; Progesterone; Randomized Controlled Trials as Topic | 2017 |
Prematurity in twin pregnancies.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Biomarkers; Cerclage, Cervical; Estrogen Antagonists; Female; Fibronectins; Gestational Age; Humans; Hydroxyprogesterones; Incidence; Infant, Newborn; Infant, Premature; Monitoring, Ambulatory; New York; Pregnancy; Pregnancy, Multiple; Premature Birth; Prenatal Diagnosis; Risk Factors; Tocolysis; Twins; Twins, Dizygotic; Twins, Monozygotic; Ultrasonography, Prenatal | 2009 |
Pharmacological use of progesterone and 17-alpha-hydroxyprogesterone caproate in the prevention of preterm delivery.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abortion, Habitual; Anti-Inflammatory Agents; Female; Humans; Hydrocortisone; Hydroxyprogesterones; Infant, Newborn; Obstetric Labor, Premature; Pregnancy; Pregnancy Maintenance; Pregnancy Outcome; Progesterone; Progesterone Congeners; Prostaglandins; Randomized Controlled Trials as Topic | 2009 |
What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Pregnancy Complications; Premature Birth; Progesterone; Progestins; Recurrence; Treatment Outcome | 2011 |
17α Hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abnormalities, Drug-Induced; Animals; Cost Savings; Cost-Benefit Analysis; Drug Administration Schedule; Drug Costs; Evidence-Based Medicine; Female; Gestational Age; Humans; Hydroxyprogesterones; Injections; Pregnancy; Premature Birth; Recurrence; Risk Assessment; Risk Factors | 2012 |
Prevention of preterm labour: 2011 update on tocolysis.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adrenergic beta-Agonists; Anti-Bacterial Agents; Calcium Channel Blockers; Cyclooxygenase Inhibitors; Female; Humans; Hydroxyprogesterones; Magnesium Sulfate; Obstetric Labor, Premature; Pregnancy; Progesterone; Receptors, Oxytocin; Tocolysis; Tocolytic Agents | 2011 |
The safety of progesterone and 17-hydroxyprogesterone caproate administration for the prevention of preterm birth: an evidence-based assessment.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abortion, Spontaneous; Animals; Blood Glucose; Clinical Trials as Topic; Female; Fetal Death; Fetal Development; Hormone Antagonists; Humans; Hydroxyprogesterones; Immunity, Innate; Pregnancy; Pregnancy, Multiple; Premature Birth; Progesterone; Progestins; Receptors, Progesterone; Stillbirth | 2012 |
Technique modifications for reducing the risks from amniocentesis or chorionic villus sampling.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Amniocentesis; Chorionic Villi Sampling; Female; Gestational Age; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy Trimester, Second; Progesterone; Randomized Controlled Trials as Topic; Tocolysis | 2012 |
Recurrent hope for the treatment of preterm delivery.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abortion, Habitual; Anti-Bacterial Agents; Clinical Trials as Topic; Female; Humans; Hydroxyprogesterones; Obstetric Labor, Premature; Pregnancy; Pregnancy Outcome; Risk Factors; Treatment Outcome | 2003 |
Progestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adolescent; Adult; Confidence Intervals; Female; Follow-Up Studies; Gestational Age; Humans; Hydroxyprogesterones; Incidence; Medroxyprogesterone Acetate; Odds Ratio; Pregnancy; Pregnancy Outcome; Pregnancy, High-Risk; Premature Birth; Prenatal Care; Randomized Controlled Trials as Topic; Reference Values; Risk Assessment; Treatment Outcome | 2005 |
Role of progestogens for the prevention of premature birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxypregnenolone; Cervix Uteri; Female; Humans; Hydroxyprogesterones; Practice Patterns, Physicians'; Pregnancy; Pregnancy Complications, Infectious; Premature Birth; Progestins; Uterus | 2005 |
Prevention and treatment of pregnancy-induced hypertension (preeclampsia) with progestogens.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Dydrogesterone; Female; Humans; Hydroxyprogesterones; Hypertension, Pregnancy-Induced; Pre-Eclampsia; Pregnancy; Pregnancy Trimester, Third; Progestins | 2005 |
Medical cost savings associated with 17 alpha-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Cost Savings; Female; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth | 2007 |
Idiopathic vertebral abscess in pregnancy: case report and literature review.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abscess; Adult; Cesarean Section; Female; Humans; Hydroxyprogesterones; Injections, Intramuscular; Magnetic Resonance Imaging; Osteomyelitis; Pregnancy; Pregnancy Complications, Infectious; Progestins; Spinal Diseases | 2007 |
Subgroup analysis in obstetrics clinical trials.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Anti-Bacterial Agents; Black or African American; Female; Humans; Hydroxyprogesterones; Obstetric Labor, Premature; Pregnancy; Probability; Randomized Controlled Trials as Topic; Research Design; Vaginosis, Bacterial; White People | 2007 |
Prevention of preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Bed Rest; Cervix Uteri; Coitus; Female; Humans; Hydroxyprogesterones; Infections; Nutritional Physiological Phenomena; Obstetric Labor, Premature; Patient Education as Topic; Pregnancy; Progesterone; Risk; Socioeconomic Factors | 1981 |
Progestogen administration in pregnancy may prevent preterm delivery.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abortion, Threatened; Female; Humans; Hydroxyprogesterones; Meta-Analysis as Topic; Obstetric Labor, Premature; Pregnancy; Progesterone Congeners; Randomized Controlled Trials as Topic | 1990 |
73 trial(s) available for 17 alpha-hydroxyprogesterone caproate and Pregnancy
| Article | Year |
|---|---|
Comparison the efficacy of vaginal progesterone
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Caproates; Cerclage, Cervical; Enterocolitis, Necrotizing; Female; Humans; Infant, Newborn; Iran; Pregnancy; Pregnant Women; Premature Birth; Progesterone; Prospective Studies | 2022 |
Weekly 17 alpha-hydroxyprogesterone caproate to prevent preterm birth among women living with HIV: a randomised, double-blind, placebo-controlled trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adolescent; Double-Blind Method; Female; Gestational Age; HIV Infections; Humans; Infant, Newborn; Pregnancy; Premature Birth; Zambia | 2021 |
Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Premature Birth; Progesterone; Progestins | 2022 |
Comparison of oral Dydrogesterone and 17-α hydroxyprogesterone caprate in the prevention of preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Oral; Adult; Dydrogesterone; Female; Humans; Injections, Intramuscular; Obstetric Labor, Premature; Pregnancy; Pregnancy Outcome; Premature Birth; Progestins; Treatment Outcome | 2022 |
Should we stop prescribing IM progesterone to women with a history of preterm labor?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Infant, Newborn; Pregnancy; Premature Birth; Progesterone; United States; United States Food and Drug Administration | 2022 |
Effect of weekly 17-hydroxyprogesterone caproate on small for gestational age among pregnant women with HIV in Zambia.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Female; Gestational Age; HIV Infections; Humans; Hydroxyprogesterones; Infant; Pregnancy; Pregnant Women; Premature Birth; Zambia | 2022 |
Effect of 17-Hydroxyprogesterone Caproate on Interleukin-6 and Tumor necrosis factor-alpha in expectantly managed early-onset preeclampsia.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Female; Humans; Infant, Newborn; Interleukin-6; Pre-Eclampsia; Pregnancy; Tumor Necrosis Factor-alpha | 2023 |
17-OHPC to Prevent Recurrent Preterm Birth in Singleton Gestations (PROLONG Study): A Multicenter, International, Randomized Double-Blind Trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Double-Blind Method; Female; Gestational Age; Humans; Infant, Newborn; Infant, Newborn, Diseases; Injections, Intramuscular; Perinatal Death; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Premature Birth; Progestins; Secondary Prevention; Treatment Failure | 2020 |
Intramuscular 17α-hydroxyprogesterone caproate to decrease preterm delivery in women with placenta praevia: a randomised controlled trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cesarean Section; Female; Gestational Age; Humans; Infant, Newborn; Injections, Intramuscular; Placenta Previa; Pregnancy; Premature Birth; Tocolytic Agents | 2020 |
Adherence rates and outcomes for 17-hydroxyprogesterone caproate use in women with a previous history of preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Adult; Female; Humans; Hydroxyprogesterones; Infant; Infant, Newborn; Pregnancy; Premature Birth; Retrospective Studies; United States | 2020 |
The effect of omega-3 supplementation on pregnancy outcomes by smoking status.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Dietary Supplements; Fatty Acids, Omega-3; Female; Humans; Hydroxyprogesterones; Infant, Low Birth Weight; Infant, Newborn; Injections, Intramuscular; Pregnancy; Premature Birth; Progestins; Smoking; United States | 2017 |
Racial Disparities in Delivery Gestational Age among Twin Pregnancies.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Birth Weight; Black or African American; Double-Blind Method; Female; Gestational Age; Humans; Infant; Infant Mortality; Infant, Newborn; Male; North Carolina; Pregnancy; Pregnancy Outcome; Pregnancy, Twin; Premature Birth; Prospective Studies; Survival Analysis; White People; Young Adult | 2017 |
Progestogens for Maintenance Tocolysis in Women With a Short Cervix: A Randomized Controlled Trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Adult; Cervix Uteri; Female; Humans; Hydroxyprogesterones; Injections, Intramuscular; Pregnancy; Premature Birth; Treatment Outcome; Ultrasonography, Prenatal | 2017 |
Impact of Obesity on the Rate of Recurrent Spontaneous Preterm Birth in Women Treated with 17-alpha Hydroxyprogesterone Caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Body Mass Index; Female; Gestational Age; Humans; Logistic Models; Obesity; Pregnancy; Premature Birth; Progestins; Recurrence; Young Adult | 2018 |
A Double-Blind, Randomized, Placebo-Controlled Trial of 17 Alpha-hydroxyprogesterone Caproate in the Management of Preterm Premature Rupture of Membranes.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; California; Double-Blind Method; Female; Fetal Membranes, Premature Rupture; Gestational Age; Humans; Infant, Newborn; Pregnancy; Pregnancy Outcome; Premature Birth; Progestins; Time Factors; Treatment Outcome | 2018 |
Obstetric History and Likelihood of Preterm Birth of Twins.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Estrogen Antagonists; Female; Gestational Age; Humans; Infant, Newborn; Logistic Models; Pregnancy; Pregnancy Outcome; Pregnancy, Twin; Premature Birth; Recurrence; Risk Assessment; Risk Factors; Treatment Failure; United States; Young Adult | 2018 |
A randomised trial to compare 200 mg micronised progesterone effervescent vaginal tablet daily with 250 mg intramuscular 17 alpha hydroxy progesterone caproate weekly for prevention of recurrent preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Adult; Drug Administration Schedule; Female; Humans; Hydroxyprogesterones; Injections, Intramuscular; Pregnancy; Premature Birth; Progesterone; Progestins; Recurrence; Secondary Prevention; Treatment Outcome | 2018 |
PROLONG Clinical Study Protocol: Hydroxyprogesterone Caproate to Reduce Recurrent Preterm Birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Gestational Age; Humans; Infant; Infant Mortality; Infant, Newborn; Injections, Intramuscular; Multicenter Studies as Topic; Pregnancy; Premature Birth; Progestins; Randomized Controlled Trials as Topic; Treatment Outcome | 2018 |
Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Anti-HIV Agents; Clinical Trials, Phase III as Topic; Developing Countries; Female; Gestational Age; HIV Infections; Humans; Injections, Intramuscular; Live Birth; Pregnancy; Pregnancy Complications, Infectious; Premature Birth; Progestins; Randomized Controlled Trials as Topic; Stillbirth; Zambia | 2019 |
Prevention of preterm delivery by 17 alpha-hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cervix Uteri; Female; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy, Twin; Premature Birth; Progestins; Treatment Outcome; Ultrasonography | 2013 |
Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Fatty Acids, Omega-3; Female; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy Trimester, Second; Premature Birth; Recurrence | 2014 |
The use of 17-hydroxy progesterone in women with arrested preterm labor: a randomized clinical trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Apgar Score; Birth Weight; Female; Gestational Age; Humans; Hydroxyprogesterones; Infant, Newborn; Obstetric Labor, Premature; Pregnancy; Pregnancy Outcome; Premature Birth; Tocolysis | 2014 |
Fetal fibronectin versus cervical length as predictors of preterm birth in twin pregnancy with or without 17-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cervical Length Measurement; Cervix Uteri; Estrogen Antagonists; Female; Fibronectins; Gestational Age; Humans; Hydroxyprogesterones; Predictive Value of Tests; Pregnancy; Pregnancy, Twin; Premature Birth; Ultrasonography, Prenatal; Vagina | 2014 |
A randomised controlled double-blind clinical trial of 17-hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Double-Blind Method; Female; Gestational Age; Humans; Hydroxyprogesterones; Infant, Newborn; Infant, Premature; Infant, Very Low Birth Weight; Injections, Intramuscular; Odds Ratio; Pregnancy; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Pregnancy, Twin; Premature Birth; Progestins; Respiratory Distress Syndrome, Newborn; Retinopathy of Prematurity; Sepsis | 2015 |
17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hydroxyprogesterones; Injections, Intramuscular; Intention to Treat Analysis; Pregnancy; Premature Birth; Prenatal Care; Progestins; Proportional Hazards Models; Risk Factors; Treatment Outcome; Urogenital Abnormalities; Uterine Cervical Incompetence; Uterus | 2015 |
17-hydroxyprogesterone caproate for preterm rupture of the membranes: a multicenter, randomized, double-blind, placebo-controlled trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cerebral Hemorrhage; Double-Blind Method; Early Termination of Clinical Trials; Enterocolitis, Necrotizing; Female; Fetal Membranes, Premature Rupture; Gestational Age; Humans; Hydroxyprogesterones; Infant, Newborn; Infant, Premature; Injections, Intramuscular; Leukomalacia, Periventricular; Perinatal Mortality; Pregnancy; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Progestins; Proportional Hazards Models; Respiratory Distress Syndrome, Newborn; Sepsis; Time Factors; Treatment Outcome; Watchful Waiting; Young Adult | 2015 |
Does 17-alpha hydroxyprogesterone caproate prevent recurrent preterm birth in obese women?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Body Mass Index; Female; Gestational Age; Humans; Hydroxyprogesterones; Obesity; Pregnancy; Premature Birth; Progesterone Congeners; Recurrence | 2015 |
Efficacy of midtrimester short cervix interventions is conditional on intraamniotic inflammation.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Amniocentesis; Amniotic Fluid; Cerclage, Cervical; Cervical Length Measurement; Cervix Uteri; Chemokine CCL2; Chemokine CCL3; Chemokine CCL4; Cytokines; Female; Granulocyte Colony-Stimulating Factor; Humans; Hydroxyprogesterones; Inflammation; Interleukins; Pregnancy; Pregnancy Trimester, Second; Premature Birth; Progestins; Proportional Hazards Models; Risk Assessment; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult | 2016 |
A randomized controlled trial of intramuscular versus vaginal progesterone for the prevention of recurrent preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Adult; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Injections, Intramuscular; Pregnancy; Pregnancy Outcome; Premature Birth; Progestins; Prospective Studies; Tertiary Care Centers; United States; Young Adult | 2016 |
Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Decision Support Techniques; Drug Administration Schedule; Estrogen Antagonists; Female; Humans; Hydroxyprogesterones; Injections, Intramuscular; Logistic Models; Male; Pregnancy; Premature Birth; Prospective Studies; Recurrence; Risk Assessment; Risk Factors; Treatment Failure | 2016 |
Smoking, 17 Alpha-Hydroxyprogesterone Caproate, and Preterm Birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Gestational Age; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth; Prevalence; Progestins; Secondary Prevention; Smoking; Young Adult | 2016 |
17-alpha-hydroxyprogesterone caproate versus vaginal progesterone suppository for the prevention of preterm birth in women with a sonographically short cervix: A randomized controlled trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adolescent; Adult; Cervical Length Measurement; Cervix Uteri; Female; Gestational Age; Humans; Hydroxyprogesterones; Obstetric Labor, Premature; Pregnancy; Pregnancy Complications; Premature Birth; Progesterone; Prospective Studies; Suppositories; Treatment Outcome; Ultrasonography; Young Adult | 2017 |
Effect of partial compliance on the prevention of recurrent preterm birth in women receiving weekly 17 alpha-hydroxyprogesterone caproate injections.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Gestational Age; Humans; Hydroxyprogesterones; Infant, Newborn; Injections, Intramuscular; Medication Adherence; Pregnancy; Premature Birth; Recurrence; Treatment Outcome; Young Adult | 2017 |
17alpha-hydroxy-progesterone effects on cervical proinflammatory agents in women at risk for preterm delivery.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cervical Ripening; Cervix Uteri; Colorimetry; Cytokines; Female; Humans; Hydroxyprogesterones; Interleukin-1beta; Interleukin-6; Interleukin-8; Obstetric Labor, Premature; Pregnancy; Progesterone Congeners; Prospective Studies; Tumor Necrosis Factor-alpha | 2008 |
Estrus induction and fertility rates in response to exogenous hormonal administration in postpartum anestrous and subestrus bovines and buffaloes.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Animals; Buffaloes; Cattle; Dinoprost; Estrous Cycle; Estrus Synchronization; Female; Fertility; Fertility Agents, Female; Hydroxyprogesterones; Pregnancy; Progesterone | 2008 |
Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Humans; Hydroxyprogesterones; Injections, Intramuscular; Pregnancy; Premature Birth; Progestins; Risk; Treatment Failure; Triplets | 2009 |
A randomized trial of cerclage vs. 17 alpha-hydroxyprogesterone caproate for treatment of short cervix.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cerclage, Cervical; Cervical Length Measurement; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Injections, Intramuscular; Obstetric Labor, Premature; Pregnancy; Pregnancy Outcome; Pregnancy Trimester, Second; Risk Factors; Uterine Cervical Incompetence; Young Adult | 2009 |
Progesterone does not prevent preterm births in women with twins.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adolescent; Adult; Double-Blind Method; Female; Fetal Membranes, Premature Rupture; Humans; Hydroxyprogesterones; Infant, Newborn; Infant, Premature, Diseases; Injections, Intramuscular; Pregnancy; Premature Birth; Progestins; Treatment Failure; Twins; Young Adult | 2009 |
The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Diabetes, Gestational; Double-Blind Method; Female; Humans; Hydroxyprogesterones; Multivariate Analysis; Pregnancy; Pregnancy, Multiple; Progestins; Risk Factors | 2009 |
Omega-3 fatty acid supplementation to prevent recurrent preterm birth: a randomized controlled trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Dietary Supplements; Double-Blind Method; Fatty Acids, Omega-3; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Injections, Intramuscular; Pregnancy; Premature Birth; Progesterone Congeners; Recurrence | 2010 |
17-alpha-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cerclage, Cervical; Cervical Length Measurement; Female; Fetal Death; Humans; Hydroxyprogesterones; Infant, Newborn; Logistic Models; Multivariate Analysis; Perinatal Mortality; Pregnancy; Premature Birth; Progestins; Treatment Outcome; Uterine Cervical Incompetence; Young Adult | 2010 |
Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17-α hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cervix Uteri; Double-Blind Method; Female; Gestational Age; Humans; Hydroxyprogesterones; Placebos; Pregnancy; Pregnancy Trimester, Second; Premature Birth; Risk Factors; Twins; Ultrasonography | 2010 |
17-hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Double-Blind Method; Female; Humans; Hydroxyprogesterones; Morbidity; Pregnancy; Pregnancy Outcome; Pregnancy, Multiple; Premature Birth; Progestins | 2011 |
Comparison of success rate of nifedipine, progesterone, and bed rest for inhibiting uterine contraction in threatened preterm labor.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adolescent; Adult; Bed Rest; Delayed-Action Preparations; Female; Humans; Hydroxyprogesterones; Middle Aged; Nifedipine; Obstetric Labor, Premature; Pregnancy; Progesterone Congeners; Time Factors; Tocolytic Agents; Uterine Contraction; Young Adult | 2011 |
Efficacy of 17α-hydroxyprogesterone caproate in prevention of preterm delivery.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Humans; Hydroxyprogesterones; Obstetric Labor, Premature; Pregnancy; Pregnancy Outcome; Premature Birth; Treatment Outcome | 2011 |
Progesterone receptor polymorphisms and clinical response to 17-alpha-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Double-Blind Method; Female; Gene Expression Regulation, Developmental; Gestational Age; Humans; Hydroxyprogesterones; Infant, Newborn; Infant, Premature; Logistic Models; Multivariate Analysis; Polymorphism, Single Nucleotide; Pregnancy; Pregnancy Outcome; Premature Birth; Prospective Studies; Receptors, Progesterone; Reference Values; Risk Assessment; Secondary Prevention; Treatment Outcome | 2011 |
Single dose 17 alpha-hydroxyprogesterone caproate in preterm labor: a randomized trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adrenal Cortex Hormones; Adult; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Nifedipine; Obstetric Labor, Premature; Pregnancy; Pregnancy Outcome; Progestins; Tocolytic Agents; Treatment Outcome; Young Adult | 2012 |
17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cervix Uteri; Double-Blind Method; Female; Gestational Age; Humans; Hydroxyprogesterones; Injections, Intramuscular; Intention to Treat Analysis; Pregnancy; Pregnancy Outcome; Pregnancy Trimester, Second; Pregnancy, Multiple; Premature Birth; Progesterone Congeners | 2011 |
Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Humans; Hydroxyprogesterones; Obstetric Labor, Premature; Pregnancy; Pregnancy Outcome; Premature Birth; Tocolysis; Tocolytic Agents; Treatment Outcome | 2012 |
Relationship between 17-hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Adult; Biomarkers; C-Reactive Protein; Corticotropin-Releasing Hormone; Female; Gestational Age; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy, Twin; Premature Birth; Progesterone; Progestins; Treatment Outcome | 2012 |
Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Biological Transport; Body Mass Index; Female; Fetal Blood; Humans; Hydroxyprogesterones; Placenta; Pregnancy; Progestins; Young Adult | 2012 |
Effect of 17-alpha hydroxyprogesterone caproate on cervical length in twin pregnancies.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cervical Length Measurement; Cervix Uteri; Female; Gestational Age; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Pregnancy, Twin; Premature Birth; Progestins; Uterine Cervical Incompetence | 2012 |
17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adolescent; Adult; Cervical Length Measurement; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Infant, Premature; Parity; Pregnancy; Pregnancy Outcome; Premature Birth; Progestins; Treatment Outcome; Young Adult | 2012 |
Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Birth Weight; Cerebral Hemorrhage; Double-Blind Method; Enterocolitis, Necrotizing; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Infant, Premature; Obstetric Labor, Premature; Oxygen Inhalation Therapy; Pregnancy; Pregnancy Outcome; Progesterone Congeners; Risk; Survival Analysis | 2003 |
Prevention of severe ovarian hyperstimulation syndrome (OHSS) in IVF patients by steroidal ovarian suppression--a prospective randomized study.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Chorionic Gonadotropin; Embryo Transfer; Estradiol; Female; Fertilization in Vitro; Humans; Hydroxyprogesterones; Ovarian Hyperstimulation Syndrome; Ovary; Ovulation Induction; Pregnancy; Pregnancy Rate; Progesterone; Prospective Studies; Time Factors | 2003 |
Recurrent hope for the treatment of preterm delivery.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abortion, Habitual; Anti-Bacterial Agents; Clinical Trials as Topic; Female; Humans; Hydroxyprogesterones; Obstetric Labor, Premature; Pregnancy; Pregnancy Outcome; Risk Factors; Treatment Outcome | 2003 |
17 alpha-hydroxyprogesterone caproate versus intravaginal progesterone in IVF-embryo transfer cycles: a prospective randomized study.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Adult; Embryo Transfer; Estradiol; Female; Fertilization in Vitro; Humans; Hydroxyprogesterones; Injections, Intramuscular; Luteal Phase; Oocytes; Pregnancy; Pregnancy Rate; Progesterone; Prospective Studies | 2004 |
Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adolescent; Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gestational Age; Humans; Hydroxyprogesterones; Incidence; Injections, Intramuscular; Longitudinal Studies; Pregnancy; Pregnancy Outcome; Premature Birth; Prenatal Care; Probability; Reference Values; Risk Assessment; Treatment Outcome; United States | 2005 |
Progesterone for the prevention of preterm birth in women with multiple pregnancies: the AMPHIA trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Obstetric Labor, Premature; Pregnancy; Pregnancy Outcome; Pregnancy, High-Risk; Pregnancy, Multiple; Progestins; Treatment Outcome | 2007 |
Effect of 17alpha-hydroxyprogesterone caproate before embryo transfer on the outcome of in vitro fertilization and embryo transfer: a randomized trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Embryo Transfer; Female; Fertilization in Vitro; Humans; Hydroxyprogesterones; Middle Aged; Muscle, Smooth; Pregnancy; Pregnancy Outcome; Pregnancy Rate; Progestins; Uterus | 2008 |
A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Double-Blind Method; Female; Humans; Hydroxyprogesterones; Injections, Intramuscular; Pregnancy; Pregnancy Outcome; Pregnancy, Multiple; Premature Birth; Progesterone Congeners; Treatment Failure; Twins | 2007 |
Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Child Development; Child, Preschool; Female; Follow-Up Studies; Humans; Hydroxyprogesterones; Infant, Newborn; Nervous System; Pregnancy; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Prenatal Exposure Delayed Effects; Progestins | 2007 |
Salivary progesterone and estriol among pregnant women treated with 17-alpha-hydroxyprogesterone caproate or placebo.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Estriol; Female; Gestational Age; Humans; Hydroxyprogesterones; Longitudinal Studies; Obstetric Labor, Premature; Placental Circulation; Pregnancy; Progesterone; Saliva | 2008 |
The effect of 17 alpha-hydroxyprogesterone caproate on pregnancy outcome in an active-duty military population.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Double-Blind Method; Estrogen Antagonists; Female; Humans; Hydroxyprogesterones; Infant Mortality; Infant, Low Birth Weight; Infant, Newborn; Infant, Premature; Military Medicine; Obstetric Labor, Premature; Outcome and Process Assessment, Health Care; Pregnancy; Prospective Studies; Random Allocation | 1983 |
Therapeutic value of indomethacin in threatened abortion.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abortion, Missed; Abortion, Threatened; Clinical Trials as Topic; Female; Humans; Hydroxyprogesterones; Indomethacin; Parasympatholytics; Pregnancy; Pregnancy Trimester, First; Pregnancy Trimester, Second | 1980 |
Inefficacy of 17 alpha-hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Double-Blind Method; Estrogens; Female; Hydroxyprogesterones; Obstetric Labor, Premature; Placental Lactogen; Pregnancy; Pregnancy Trimester, Third; Pregnancy, Multiple; Progesterone; Testosterone; Twins | 1980 |
17-alpha-Hydroxyprogesterone caproate and natural progesterone in assisted reproduction: a comparative study.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Embryo Transfer; Female; Fertilization in Vitro; Humans; Hydroxyprogesterones; Pregnancy; Progesterone; Progesterone Congeners | 1997 |
A prospective randomized study comparing intramuscular progesterone and 17alpha-hydroxyprogesterone caproate in patients undergoing in vitro fertilization-embryo transfer cycles.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Embryo Transfer; Female; Fertilization in Vitro; Humans; Hydroxyprogesterones; Infertility, Female; Injections, Intramuscular; Male; Outcome Assessment, Health Care; Pregnancy; Progesterone; Prospective Studies | 2001 |
The effect of 17 alpha-hydroxyprogesterone caproate/oestradiol valerate on the development and outcome of early pregnancies following in vitro fertilization and embryo transfer: a prospective and randomized controlled trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Embryo Transfer; Estradiol; Estrogens, Conjugated (USP); Female; Fertilization in Vitro; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy Outcome; Progesterone Congeners; Progestins; Prospective Studies; Retrospective Studies | 1992 |
Progestogen administration in pregnancy may prevent preterm delivery.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abortion, Threatened; Female; Humans; Hydroxyprogesterones; Meta-Analysis as Topic; Obstetric Labor, Premature; Pregnancy; Progesterone Congeners; Randomized Controlled Trials as Topic | 1990 |
Endocrine effects of 17 alpha-hydroxyprogesterone caproate during early pregnancy: a double-blind clinical trial.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Abortion, Spontaneous; Double-Blind Method; Estrogen Antagonists; Female; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy Trimester, First; Prolactin; Random Allocation; Thyroxine; Thyroxine-Binding Proteins | 1988 |
Trial of 17-hydroxyprogesterone caproate (Proluton Depot) in women with long-standing infertility; failure of estrogen positive feedback the following cycle.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abortion, Habitual; Adult; Clinical Trials as Topic; Double-Blind Method; Embryo Implantation; Estrogens; Feedback; Female; Follicle Stimulating Hormone; Humans; Hydroxyprogesterones; Infertility, Female; Injections, Intramuscular; Luteinizing Hormone; Menstrual Cycle; Pregnancy; Random Allocation | 1987 |
Support of the luteal phase in in vitro fertilization programs: results of a controlled trial with intramuscular Proluton.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Chorionic Gonadotropin; Clinical Trials as Topic; Clomiphene; Female; Fertilization in Vitro; Humans; Hydroxyprogesterones; Injections, Intramuscular; Luteal Phase; Luteinizing Hormone; Menotropins; Pregnancy | 1985 |
205 other study(ies) available for 17 alpha-hydroxyprogesterone caproate and Pregnancy
| Article | Year |
|---|---|
Revisiting the placental clock: Early corticotrophin-releasing hormone rise in recurrent preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Area Under Curve; Cohort Studies; Corticotropin-Releasing Hormone; Enzyme-Linked Immunosorbent Assay; Female; Gestational Age; Humans; Placenta; Pregnancy; Pregnancy Outcome; Premature Birth; Prenatal Care; Prospective Studies; Radioimmunoassay; Risk Factors; ROC Curve; Up-Regulation | 2021 |
In utero exposure to 17α-hydroxyprogesterone caproate and risk of cancer in offspring.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; California; Female; Humans; Incidence; Male; Middle Aged; Neoplasms; Pregnancy; Pregnancy Trimesters; Prenatal Exposure Delayed Effects; Registries | 2022 |
A Possible Mechanism of Action of 17α-Hydroxyprogesterone Caproate: Enhanced IL-10 Production.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Interleukin-10; Leukocytes, Mononuclear; Lipopolysaccharides; Pregnancy; Premature Birth; Tumor Necrosis Factor-alpha | 2023 |
Eligibility, Utilization, and Effectiveness of 17-Alpha Hydroxyprogesterone Caproate in a Statewide Population-Based Cohort of Medicaid Enrollees.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Medicaid; Pregnancy; Premature Birth; Retrospective Studies | 2023 |
Changes in the Use of Hydroxyprogesterone Caproate Injection After Confirmatory Trial Failure.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Pregnancy; Premature Birth; Progestins | 2022 |
A Comparison of Vaginal and Intramuscular Progesterone for the Prevention of Recurrent Preterm Birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Premature Birth; Progesterone; Retrospective Studies | 2023 |
Can 17 hydroxyprogesterone caproate (17P) decrease preterm deliveries in patients with a history of PMC or pPROM?
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Female; Fetal Membranes, Premature Rupture; Humans; Infant, Newborn; Obstetric Labor, Premature; Pregnancy; Premature Birth; Retrospective Studies | 2022 |
Regional differences in utilization of 17α-hydroxyprogesterone caproate (17-OHP).
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Cohort Studies; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Premature Birth; Retrospective Studies | 2022 |
Society for Maternal-Fetal Medicine Statement: Response to the Food and Drug Administration's withdrawal of 17-alpha hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Perinatology; Pregnancy; Premature Birth; Progesterone; United States; United States Food and Drug Administration | 2023 |
Vaginal Progesterone Is Associated with Intrahepatic Cholestasis of Pregnancy.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Cholestasis, Intrahepatic; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Premature Birth; Progesterone; Progestins | 2023 |
Addressing a broken drug pipeline for preterm birth: why early preterm birth is an orphan disease.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Pharmaceutical Preparations; Pregnancy; Premature Birth; Rare Diseases; United States | 2023 |
The Effect of Intramuscular 17α-Hydroxyprogesterone in Women Screened for Shortened Cervical Length.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cerclage, Cervical; Cervical Length Measurement; Cervix Uteri; Female; Fetal Membranes, Premature Rupture; Gestational Age; Humans; Infant, Newborn; Injections, Intramuscular; Pregnancy; Pregnancy Trimester, Second; Premature Birth; Progestins; Retrospective Studies; Treatment Failure | 2020 |
Confirmatory Trial for Drug to Prevent Preterm Birth Finds No Benefit, So Why Is It Still Prescribed?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Clinical Trials as Topic; Conflict of Interest; Drug and Narcotic Control; Drug Industry; Female; Fetal Death; Humans; Infant, Newborn; Obstetrics; Perinatal Death; Pregnancy; Premature Birth; Progestins; Research Design; Societies, Medical; Treatment Failure; United States; United States Food and Drug Administration | 2020 |
SMFM Statement: Use of 17-alpha hydroxyprogesterone caproate for prevention of recurrent preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Pregnancy; Premature Birth; Progestins; Recurrence | 2020 |
Accelerated Approval of 17α-Hydroxyprogesterone Caproate: A Cautionary Tale.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Clinical Trials as Topic; Drug Approval; Female; Humans; Infant, Newborn; Perinatal Mortality; Pregnancy; Premature Birth; Treatment Outcome; United States; United States Food and Drug Administration | 2020 |
Developmental exposure to 17α-hydroxyprogesterone caproate impairs adult delayed reinforcement and reversal learning in male and female rats.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Animals; Animals, Newborn; Behavior, Animal; Conditioning, Operant; Delay Discounting; Female; Male; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Long-Evans; Reinforcement, Psychology; Reversal Learning | 2020 |
FDA approved vs. Pharmacy compounded 17-OHPC-current issues for obstetricians to consider in reducing recurrent preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Drug Approval; Drug Compounding; Drug Labeling; Female; Humans; Infant, Newborn; Pharmaceutical Services; Pregnancy; Premature Birth; Recurrence; United States; United States Food and Drug Administration | 2020 |
Re-examining the Meis Trial for Evidence of False-Positive Results.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Pregnancy; Premature Birth; Progestins; Randomized Controlled Trials as Topic; Reproducibility of Results; Treatment Outcome | 2020 |
The association between 17-hydroxyprogesterone caproate use and postpartum hemorrhage.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Estrogen Antagonists; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Postpartum Hemorrhage; Pregnancy; Premature Birth; Progestins; Retrospective Studies | 2019 |
17-Hydroxyprogesterone caproate improves hypertension and renal endothelin-1 in response to sFlt-1 induced hypertension in pregnant rats.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Animals; Blood Pressure; Endothelin-1; Female; Humans; Hypertension; Kidney; Pregnancy; Rats; Rats, Sprague-Dawley; Vascular Endothelial Growth Factor A | 2020 |
A chronicle of the 17-alpha hydroxyprogesterone caproate story to prevent recurrent preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Drug and Narcotic Control; Drug Approval; Evidence-Based Medicine; Female; Humans; Observational Studies as Topic; Pregnancy; Premature Birth; Progestins; Randomized Controlled Trials as Topic; Recurrence; United States; United States Food and Drug Administration | 2021 |
Withdrawing Approval of Makena - A Proposal from the FDA Center for Drug Evaluation and Research.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Advisory Committees; Black People; Clinical Trials as Topic; Drug Approval; Europe; Female; Humans; Infant, Newborn; Pregnancy; Premature Birth; Product Recalls and Withdrawals; Progestins; Risk Factors; Treatment Outcome; United States; United States Food and Drug Administration | 2020 |
Preterm Birth and 17OHP - Why the FDA Should Not Withdraw Approval.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Black or African American; Clinical Trials as Topic; Drug Approval; Female; Health Status Disparities; Humans; Pregnancy; Premature Birth; Progestins; Risk Factors; United States; United States Food and Drug Administration | 2020 |
Recurrent Preterm Birth Reduction by 17-Hydroxyprogesterone Caproate in Dichorionic/Diamniotic Twin Gestation.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Female; Humans; Infant, Newborn; Pregnancy; Pregnancy, Twin; Premature Birth; Prospective Studies; Randomized Controlled Trials as Topic | 2022 |
Intramuscular progesterone in women with twins and a prior singleton spontaneous preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Infant, Newborn; Pregnancy; Premature Birth; Progesterone; Prospective Studies; Retrospective Studies | 2020 |
Pregnancy duration with use of 17-α-hydroxyprogesterone caproate in a retrospective cohort at high risk of recurrent preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Caproates; Cohort Studies; Female; Humans; Hydroxyprogesterones; Infant; Infant, Newborn; Pregnancy; Premature Birth; Retrospective Studies | 2020 |
Enhanced drug delivery to the reproductive tract using nanomedicine reveals therapeutic options for prevention of preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Animals; Female; Nanomedicine; Pharmaceutical Preparations; Pregnancy; Premature Birth; Progesterone; Progestins | 2021 |
17-hydroxyprogesterone caproate for women with congenital uterine anomalies: does it impact the risk of recurrent preterm birth?
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Female; Humans; Infant, Newborn; Pregnancy; Premature Birth; Urogenital Abnormalities; Uterus | 2021 |
17-alpha hydroxyprogesterone caproate and risk for venous thromboembolism during pregnancy.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Infant, Newborn; Pregnancy; Premature Birth; Progestins; Retrospective Studies; Venous Thromboembolism | 2022 |
Utilization of hydroxyprogesterone caproate among pregnancies with live birth deliveries in the sentinel distributed database.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Computer Communication Networks; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Live Birth; Pregnancy; Premature Birth; Progesterone; United States | 2022 |
Utilization, adherence, and outcomes of 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hypertension; Infant, Newborn; Injections, Intramuscular; Pregnancy; Premature Birth; United States | 2021 |
Preventing recurrent preterm birth with 125 mg of 17-alpha-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Caproates; Female; Gestational Age; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Premature Birth; Retrospective Studies | 2021 |
Performance on a modified signal detection task of attention is impaired in male and female rats following developmental exposure to the synthetic progestin, 17α-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Animals; Attention; Female; Humans; Male; Pregnancy; Premature Birth; Progestins; Rats | 2021 |
Developmental exposure to the synthetic progestin, 17α-hydroxyprogesterone caproate, disrupts the mesocortical serotonin pathway and alters impulsive decision-making in rats.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Animals; Female; Humans; Infant, Newborn; Pregnancy; Premature Birth; Progestins; Rats; Reward; Serotonin | 2021 |
Operationalizing 17α-Hydroxyprogesterone Caproate to Prevent Recurrent Preterm Birth: Definitions, Barriers, and Next Steps.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Gestational Age; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Premature Birth; Progestins | 2017 |
The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cytochrome P-450 CYP3A; Female; Gestational Age; Humans; Hydroxyprogesterones; Polymorphism, Single Nucleotide; Pregnancy; Premature Birth; Progestins; Receptors, Progesterone | 2017 |
Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Bronchopulmonary Dysplasia; Cerebral Hemorrhage; Cohort Studies; Enterocolitis, Necrotizing; Female; Gestational Age; Humans; Hydroxyprogesterones; Infant; Infant Mortality; Leukomalacia, Periventricular; Male; North Carolina; Pregnancy; Premature Birth; Progestins; Recurrence; Retrospective Studies | 2017 |
Prevention of Preterm Labor with 17α-Hydroxyprogesterone (17OHP) Caproate: A Comparison of Adverse Drug Reaction Rates between Compounded and Commercial Formulations.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Drug Compounding; Drug-Related Side Effects and Adverse Reactions; Female; Gestational Age; Humans; Hydroxyprogesterones; Medication Adherence; Pregnancy; Premature Birth; Retrospective Studies; Young Adult | 2017 |
Adjuvant administration of 17-α-hydroxy-progesterone caproate in women with three or more second trimester pregnancy losses undergoing cervical cerclage is no more effective than cerclage alone.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cerclage, Cervical; Cohort Studies; Estrogen Antagonists; Female; Humans; Hydroxyprogesterones; Injections, Intramuscular; Pregnancy; Pregnancy Outcome; Pregnancy Trimester, Second; Premature Birth; Retrospective Studies; United States; Uterine Cervical Incompetence | 2018 |
Personalised medicine-the potential yet realised.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Case-Control Studies; Female; Humans; Pharmacogenetics; Precision Medicine; Pregnancy; Premature Birth | 2018 |
Optimal routes of administration, vehicles and timing of progesterone treatment for inhibition of delivery during pregnancy.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Cutaneous; Administration, Rectal; Animals; Drug Administration Schedule; Drug Carriers; Female; Hydroxyprogesterones; Injections, Subcutaneous; Pregnancy; Premature Birth; Progesterone; Progestins; Rats; Treatment Outcome | 2017 |
Evaluation of Progesterone Utilization and Birth Outcomes in a State Medicaid Plan.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cohort Studies; Cost-Benefit Analysis; Drug Utilization Review; Female; Gestational Age; Humans; Hydroxyprogesterones; Massachusetts; Medicaid; Medication Adherence; Pregnancy; Pregnancy Outcome; Premature Birth; Progesterone; Retrospective Studies; United States; Young Adult | 2017 |
Utilization, Cost, and Outcome of Branded vs Compounded 17-Alpha Hydroxyprogesterone Caproate in Prevention of Preterm Birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Databases, Factual; Drug Costs; Drug Utilization; Female; Humans; Infant, Newborn; Pregnancy; Premature Birth; Progestins | 2017 |
In an in-vitro model using human fetal membranes, 17-α hydroxyprogesterone caproate is not an optimal progestogen for inhibition of fetal membrane weakening.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Extraembryonic Membranes; Female; Fetal Membranes, Premature Rupture; Granulocyte-Macrophage Colony-Stimulating Factor; Hemostatics; Humans; Hydroxyprogesterones; In Vitro Techniques; Models, Biological; Pregnancy; Premature Birth; Progestins; Thrombin; Tumor Necrosis Factor-alpha | 2017 |
Progesterone for Prevention of Preterm Birth: Shortcomings and Unintended Consequences of the Orphan Drug Act.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Drug Approval; Drug Costs; Estrogen Antagonists; Female; Health Services Accessibility; Healthcare Disparities; Humans; Hydroxyprogesterones; Louisiana; Medicaid; Needs Assessment; Orphan Drug Production; Pregnancy; Pregnancy, High-Risk; Premature Birth; Quality Improvement; United States; United States Food and Drug Administration | 2017 |
Impact of Pregnancy History and 17-Hydroxyprogesterone Caproate on Cervical Cytokines and Matrix Metalloproteinases.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Body Fluids; Cervix Uteri; Cytokines; Female; Gestational Age; Humans; Matrix Metalloproteinases; Parity; Pregnancy; Premature Birth; Prospective Studies; United States; Young Adult | 2018 |
Limitations of cohort studies with historic controls.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Cohort Studies; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Premature Birth; Prospective Studies | 2018 |
Epigenetic Regulation of the Nitric Oxide Pathway, 17-α Hydroxyprogesterone Caproate, and Recurrent Preterm Birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Case-Control Studies; CpG Islands; Epigenesis, Genetic; Estrogen Antagonists; Female; Gene Expression; Gestational Age; Humans; Infant, Newborn; Methylation; Nitric Oxide; Pregnancy; Premature Birth; Prospective Studies; Recurrence; Risk Factors; Signal Transduction | 2018 |
Response to 17-alpha hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Premature Birth; Progestins; Prospective Studies | 2018 |
Reply.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Pregnancy; Premature Birth; Prospective Studies | 2018 |
17OHP-C in patients with spontaneous preterm labor and intact membranes: is there an effect according to the presence of intra-amniotic inflammation?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Amnion; Amniotic Fluid; Cohort Studies; Estrogen Antagonists; Female; Gestational Age; Humans; Inflammation; Interleukin-8; Obstetric Labor, Premature; Pregnancy; Retrospective Studies; Young Adult | 2018 |
Inequality and Innovation: Barriers and Facilitators to 17P Administration to Prevent Preterm Birth among Medicaid Participants.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; District of Columbia; Female; Healthcare Disparities; Humans; Hydroxyprogesterones; Infant, Newborn; Medicaid; Mothers; Pregnancy; Premature Birth; Prenatal Care; Puerto Rico; Socioeconomic Factors; United States | 2018 |
Defining the clinical response to 17-alpha hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Gestational Age; Humans; Pregnancy; Pregnancy Outcome; Premature Birth; Progestins; Randomized Controlled Trials as Topic; Time Factors | 2018 |
Reducing Barriers to 17-Hydroxprogestrone Caproate (17P) Injections to Prevent Recurrent Preterm Birth in Mississippi.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Education, Medical; Female; Health Services Accessibility; Humans; Hydroxyprogesterones; Mississippi; Pregnancy; Premature Birth; Progestins; Recurrence | 2016 |
Barriers and Facilitators to Recurrent Preterm Birth Prevention among Low-Income Women: A Qualitative Study.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Attitude to Health; Female; Health Status Disparities; Humans; Injections, Intramuscular; Patient Satisfaction; Physician-Patient Relations; Poverty; Pregnancy; Premature Birth; Recurrence; Risk Factors; Secondary Prevention | 2019 |
Disparities in 17-Hydroxyprogesterone Caproate Offer and Uptake in Pregnancies at a Risk of Preterm Birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Healthcare Disparities; Humans; Insurance Coverage; Insurance, Health; Linear Models; Massachusetts; Pregnancy; Premature Birth; Progestins; Racial Groups; Retrospective Studies | 2019 |
Reply.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Infant, Newborn; Pregnancy; Premature Birth; Prospective Studies | 2019 |
Progesterone for preterm birth prevention: the importance of informed consent.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Female; Humans; Infant, Newborn; Informed Consent; Pregnancy; Premature Birth; Progesterone; Progestins; Prospective Studies | 2019 |
Progesterone effects on vaginal cytokines in women with a history of preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Adolescent; Adult; Female; Gene Expression Regulation; Gestational Age; Humans; Immunity, Innate; Infant, Newborn; Interleukin-13; Interleukin-1alpha; Interleukin-1beta; Interleukin-2; Pregnancy; Premature Birth; Progesterone; Progestins; Prospective Studies; Vagina | 2018 |
Beyond the Window: Patient Characteristics and Geographic Locations Associated with Late Prenatal Care in Women Eligible for 17-P Preterm Birth Prevention.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Age Factors; Bayes Theorem; Cohort Studies; Ethnicity; Female; Geography; Humans; Infant, Newborn; Insurance, Health; Pregnancy; Premature Birth; Prenatal Care; Racial Groups; Retrospective Studies; Risk Factors; Secondary Prevention; Smoking; United States | 2019 |
Factors Associated with Utilization of 17-Hydroxyprogesterone Caproate for the Prevention of Recurrent Preterm Birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Guideline Adherence; Hispanic or Latino; Humans; Medication Adherence; Practice Guidelines as Topic; Pregnancy; Premature Birth; Prenatal Care; Progestins; Retrospective Studies | 2020 |
Defining 17OHP-C responsiveness.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Female; Humans; Pregnancy; Premature Birth | 2019 |
Understanding barriers to uptake of 17 alpha-hydroxyprogesterone caproate (17-OHP) in women with history of preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Gestational Age; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Premature Birth; Progestins; Recurrence | 2021 |
Practical considerations with 17-Hydroxyprogesterone caproate for preterm birth prevention: does timing of initiation and compliance matter?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adolescent; Adult; Drug Administration Schedule; Estrogen Antagonists; Female; Gestational Age; Humans; Medication Adherence; Middle Aged; Obstetric Labor, Premature; Pregnancy; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Premature Birth; Recurrence; Retrospective Studies; Young Adult | 2019 |
17 α-hydroxyprogesterone caproate (Makena®): a guide to its use in the prevention of preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Pregnancy Outcome; Premature Birth | 2013 |
17 OHPC for prevention of preterm birth in twins: back to the drawing board?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Cervix Uteri; Female; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy, Twin; Premature Birth; Progestins; Ultrasonography | 2013 |
Prevention of preterm birth by progestational agents: what are the molecular mechanisms?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Animals; Cervix Uteri; Connexin 43; Cyclooxygenase 2; Female; Homeodomain Proteins; Hydroxyprogesterones; Kruppel-Like Transcription Factors; Mice; MicroRNAs; Pregnancy; Premature Birth; Progesterone; Receptors, Oxytocin; STAT5 Transcription Factor; Uterine Contraction; Uterus; Zinc Finger E-box-Binding Homeobox 1 | 2013 |
Spontaneous preterm birth in African-American and Caucasian women receiving 17α-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adolescent; Adult; Black or African American; Cervical Length Measurement; Cervix Uteri; Estrogen Antagonists; Female; Gestational Age; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy, High-Risk; Premature Birth; Retrospective Studies; Secondary Prevention; White People; Young Adult | 2014 |
Medication safety is still an issue in obstetrics 50 years after the Kefauver-Harris amendments: the case of progestogens.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Clinical Trials as Topic; Female; Humans; Hydroxyprogesterones; Legislation, Drug; Obstetrics; Patient Safety; Pregnancy; Premature Birth; Progesterone Congeners; Progestins; United States; United States Food and Drug Administration | 2013 |
Progesterone blunts vascular endothelial cell secretion of endothelin-1 in response to placental ischemia.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Animals; Disease Models, Animal; Endothelial Cells; Endothelin-1; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hydroxyprogesterones; Hypertension; Ischemia; Placenta; Placental Circulation; Pre-Eclampsia; Pregnancy; Progesterone; Progestins; Rats; Rats, Sprague-Dawley | 2013 |
Does 17-α-hydroxyprogesterone caproate affect fetal biometry and birth weight in twin pregnancy?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Biometry; Birth Weight; Body Size; Female; Gestational Age; Humans; Hydroxyprogesterones; Infant, Newborn; Male; Obstetric Labor, Premature; Pregnancy; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Pregnancy, Twin; Progestins; Risk Factors; Sex Factors; Treatment Outcome; Twins | 2013 |
The effect of intramuscular progesterone on the rate of cervical shortening.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cervical Length Measurement; Cervix Uteri; Female; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth | 2013 |
Negative effects of progesterone receptor isoform-A on human placental activity of the noncanonical NF-κB signaling.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Corticotropin-Releasing Hormone; Cyclooxygenase 2; Down-Regulation; Female; Humans; Hydroxyprogesterones; NF-kappa B; Placenta; Pregnancy; Progesterone; Protein Isoforms; Receptors, Progesterone; Signal Transduction; Up-Regulation | 2014 |
Preterm birth rates in a prematurity prevention clinic after adoption of progestin prophylaxis.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Infant, Premature; Ohio; Pregnancy; Premature Birth; Progestins; Retrospective Studies | 2014 |
Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth prevention.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Case-Control Studies; Estrogen Antagonists; Exome; Female; Genetic Variation; Humans; Hydroxyprogesterones; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Pharmacogenetics; Pregnancy; Premature Birth; Prospective Studies; Secondary Prevention; Sequence Analysis, DNA | 2014 |
There is still insufficient data to recommend screening twin pregnancies with transvaginal ultrasound cervical length, but this might change soon!
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Infant, Newborn, Diseases; Perinatal Death; Pregnancy; Pregnancy, Twin; Premature Birth; Progesterone; Progestins | 2015 |
Is 17α-hydroxyprogesterone caproate contraindicated in twin gestations?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Infant, Newborn, Diseases; Perinatal Death; Pregnancy; Pregnancy, Twin; Premature Birth; Progesterone; Progestins | 2015 |
17-hydroxyprogesterone caproate significantly improves clinical characteristics of preeclampsia in the reduced uterine perfusion pressure rat model.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Animals; Blood Pressure; Disease Models, Animal; Estrogen Antagonists; Female; Hydroxyprogesterones; Placenta; Pre-Eclampsia; Pregnancy; Pregnancy, Animal; Progesterone Congeners; Rats; Rats, Sprague-Dawley; Treatment Outcome; Uterine Artery; Vascular Resistance; Vasodilation | 2015 |
Maternal characteristics influencing the development of gestational diabetes in obese women receiving 17-alpha-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Body Mass Index; Diabetes, Gestational; Female; Humans; Hydroxyprogesterones; Injections, Intramuscular; Maternal Age; Obesity; Pregnancy; Premature Birth; Retrospective Studies; Risk Factors; Tocolytic Agents; United States | 2014 |
Why the United States preterm birth rate is declining.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Adolescent; Adult; Cerclage, Cervical; Cervical Length Measurement; Evidence-Based Medicine; Female; Humans; Hydroxyprogesterones; Practice Guidelines as Topic; Pregnancy; Pregnancy in Adolescence; Pregnancy, Multiple; Premature Birth; Progesterone; Progestins; Recurrence; Smoke-Free Policy; United States; Young Adult | 2015 |
Progestogen safety in multiple gestations: application of the Bradford Hill criteria.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adverse Drug Reaction Reporting Systems; Evidence-Based Medicine; Female; Humans; Hydroxyprogesterones; Meta-Analysis as Topic; Observational Studies as Topic; Pregnancy; Pregnancy, Multiple; Premature Birth; Progestins; Randomized Controlled Trials as Topic; Risk Assessment; Treatment Outcome | 2015 |
17α-hydroxyprogesterone caproate access in the Louisiana Medicaid population.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Drug Administration Schedule; Female; Health Services Accessibility; Humans; Hydroxyprogesterones; Infant, Newborn; Insurance Coverage; Louisiana; Medicaid; Patient Protection and Affordable Care Act; Pregnancy; Premature Birth; Prenatal Care; Recurrence; Reimbursement, Incentive; United States | 2015 |
The Effect of Progestins on Tumor Necrosis Factor α-Induced Matrix Metalloproteinase-9 Activity and Gene Expression in Human Primary Amnion and Chorion Cells In Vitro.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Amnion; Cells, Cultured; Chorion; Female; Gene Expression Regulation, Enzymologic; Humans; Hydroxyprogesterones; Matrix Metalloproteinase 9; Medroxyprogesterone Acetate; Pregnancy; Progesterone; Progestins; RNA, Messenger; Tumor Necrosis Factor-alpha | 2015 |
Relation of body mass index to frequency of recurrent preterm birth in women treated with 17-alpha hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adolescent; Adult; Body Mass Index; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Hydroxyprogesterones; Obesity; Overweight; Pregnancy; Pregnancy Complications; Premature Birth; Progestins; Recurrence; Retrospective Studies; Young Adult | 2015 |
Relationship between interpregnancy interval and cervical length in high-risk women.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Birth Intervals; Cerclage, Cervical; Cervical Length Measurement; Female; Gestational Age; Humans; Hydroxyprogesterones; Linear Models; Pregnancy; Premature Birth; Progestins; Retrospective Studies | 2016 |
Association of 17α-Hydroxyprogesterone Caproate and Risk of Infection.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Chorioamnionitis; Cohort Studies; Endometritis; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Logistic Models; Pregnancy; Premature Birth; Progestins; Retrospective Studies; Risk Factors; Sepsis; Treatment Outcome | 2015 |
Vaginal progesterone, but not 17α-hydroxyprogesterone caproate, has antiinflammatory effects at the murine maternal-fetal interface.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Animals; Anti-Inflammatory Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cervix Uteri; Decidua; Endotoxins; Escherichia coli; Female; Forkhead Transcription Factors; Hydroxyprogesterones; Interferon-gamma; Interleukin-1beta; Interleukin-2 Receptor alpha Subunit; Macrophages; Matrix Metalloproteinase 9; Mice, Inbred C57BL; Monocytes; Myometrium; Neutrophils; Pregnancy; Premature Birth; Progesterone; Progesterone Congeners | 2015 |
Use of hydroxyprogesterone caproate to prevent preterm labour in uterine didelphys: a case report.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Obstetric Labor, Premature; Pregnancy; Pregnancy Outcome; Premature Birth; Progestins; Urogenital Abnormalities; Uterus | 2016 |
Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abruptio Placentae; Adult; Estrogen Antagonists; Female; Gestational Age; Humans; Hydroxyprogesterones; Longitudinal Studies; Pregnancy; Pregnancy, High-Risk; Premature Birth; Prospective Studies; Recurrence; Risk Factors; Treatment Failure; Uterine Hemorrhage; Young Adult | 2016 |
17-Hydroxyprogesterone caproate (17OHP-C) coverage among eligible women delivering at 2 North Carolina hospitals in 2012 and 2013: A retrospective cohort study.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; North Carolina; Pregnancy; Premature Birth; Recurrence; Reproductive Control Agents; Retrospective Studies; Young Adult | 2016 |
Racial and ethnic disparities in use of 17-alpha hydroxyprogesterone caproate for prevention of preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adolescent; Adult; Asian; Black or African American; Directive Counseling; Estrogen Antagonists; Female; Healthcare Disparities; Hispanic or Latino; Humans; Hydroxyprogesterones; Illinois; Insurance, Health; Medicaid; Medication Adherence; Middle Aged; Pregnancy; Premature Birth; Retrospective Studies; United States; White People; Young Adult | 2016 |
Population pharmacokinetics of 17α-hydroxyprogesterone caproate in singleton gestation.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Body Weight; Female; Fetal Blood; Humans; Hydroxyprogesterones; Models, Biological; Pregnancy; Young Adult | 2016 |
17-α Hydroxyprogesterone Caproate for the Prevention of Recurrent Preterm Birth: One Size May Not Fit All.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hydroxyprogesterones; Obstetrics; Practice Patterns, Physicians'; Pregnancy; Pregnancy Trimester, Second; Premature Birth; Prenatal Care; United States | 2016 |
Outcomes With Cerclage Alone Compared With Cerclage Plus 17α-Hydroxyprogesterone Caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cerclage, Cervical; Cohort Studies; Female; Humans; Hydroxyprogesterones; Indomethacin; Obstetric Labor, Premature; Pregnancy; Pregnancy Outcome; Retrospective Studies | 2016 |
Operationalizing 17α-Hydroxyprogesterone Caproate to Prevent Recurrent Preterm Birth: Definitions, Barriers, and Next Steps.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Estrogen Antagonists; Female; Health Services Accessibility; Humans; Hydroxyprogesterones; Medication Adherence; Patient Selection; Pregnancy; Premature Birth; Prenatal Care; Recurrence; Secondary Prevention | 2016 |
Appropriate Use of Progesterone to Prevent Preterm Birth: Approaches to Measurement for Driving Improvement.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Infant; Infant Mortality; Infant, Newborn; Medicaid; Outcome Assessment, Health Care; Pregnancy; Premature Birth; Surveys and Questionnaires; United States | 2017 |
The choice of progestogen for the prevention of preterm birth in women with singleton pregnancy and prior preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth; Prenatal Care; Progestins; Recurrence; Risk Factors; Secondary Prevention | 2017 |
Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth: a case-control study.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Analysis of Variance; Case-Control Studies; Exome Sequencing; Female; Gestational Age; Humans; Pharmacogenetics; Pregnancy; Pregnancy Outcome; Premature Birth; Progestins; Recurrence; United States | 2018 |
17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cohort Studies; Diabetes, Gestational; Female; Gestational Age; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth; Progestins; Prospective Studies; Recurrence; Treatment Outcome | 2017 |
Transplacental transfer and metabolism of 17-alpha-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Chromatography, High Pressure Liquid; Female; Humans; Hydroxyprogesterones; Oxygen Consumption; Placenta; Pregnancy; Progesterone Congeners; Tissue Distribution; Tissue Survival; Trophoblasts | 2008 |
ACOG Committee Opinion number 419 October 2008 (replaces no. 291, November 2003). Use of progesterone to reduce preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth; Progesterone; Progestins; Secondary Prevention | 2008 |
The impact of maternal body mass on the effectiveness of 17 alpha-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Body Mass Index; Female; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth; Prospective Studies; Secondary Prevention; Tocolytic Agents; Young Adult | 2008 |
Women receiving 17-alpha-hydroxyprogesterone caproate hospitalized for preterm labor at less than 34 weeks benefit from daily perinatal nursing surveillance.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Ambulatory Care; Female; Fetal Monitoring; Hospitalization; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy Outcome; Premature Birth; Progestins; Retrospective Studies; Secondary Prevention | 2008 |
Simultaneous quantitation of 17alpha-hydroxyprogesterone caproate, 17alpha-hydroxyprogesterone and progesterone in human plasma using high-performance liquid chromatography-mass spectrometry (HPLC-MS/MS).
Topics: 17 alpha-Hydroxyprogesterone Caproate; Chromatography, High Pressure Liquid; Drug Stability; Female; Humans; Hydroxyprogesterones; Medroxyprogesterone Acetate; Methanol; Pregnancy; Progesterone; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Water | 2008 |
Safety signals of 17-OHP-C use in pregnancy and efficacy in the prevention of preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Biomarkers, Pharmacological; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Premature Birth; Progesterone Congeners; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
Effect of 17alpha-hydroxyprogesterone caproate on glucose intolerance in pregnancy.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Diabetes, Gestational; Female; Glucose Intolerance; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy Complications; Progestins | 2009 |
Uterine activity in women receiving 17 alpha-hydroxyprogesterone caproate for the prevention of preterm birth: an observational study.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Humans; Hydroxyprogesterones; Injections; Pregnancy; Premature Birth; Progestins; Retrospective Studies; Uterine Contraction | 2010 |
17-Hydroxyprogesterone blunts the hypertensive response associated with reductions in uterine perfusion pressure in pregnant rats.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Animals; Endothelin-1; Female; Hydroxyprogesterones; Ischemia; Placenta; Placental Circulation; Pregnancy; Progesterone Congeners; Rats; Tumor Necrosis Factor-alpha | 2009 |
Continuous infusion of 17-hydroxyprogesterone caproate into either the fetoplacental or intervillous circulation of a placental cotyledon attenuates vasoconstriction of the fetoplacental arteries by thromboxane mimetic U46619.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; 17 alpha-Hydroxyprogesterone Caproate; Arteries; Female; Fetus; Humans; Hydroxyprogesterones; Placenta; Pregnancy; Regional Blood Flow; Vasoconstriction | 2010 |
Metabolism of 17alpha-hydroxyprogesterone caproate, an agent for preventing preterm birth, by fetal hepatocytes.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Animals; Aryl Hydrocarbon Hydroxylases; Biocatalysis; Cytochrome P-450 CYP3A; Estrogen Antagonists; Female; Fetus; Hepatocytes; Humans; Hydroxyprogesterones; Insecta; Kinetics; Microsomes; Pregnancy; Premature Birth; Transfection | 2010 |
Using 17 α-hydroxyprogesterone caproate to impact rates of recurrent preterm delivery in clinical practice.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adolescent; Adult; Cohort Studies; Female; Home Care Services; Humans; Hydroxyprogesterones; Injections, Intramuscular; Obstetric Labor, Premature; Patient Education as Topic; Patient Satisfaction; Pregnancy; Premature Birth; Prenatal Care; Progestins; Young Adult | 2010 |
Effect of 17-alpha hydroxyprogesterone caproate on the production of tumor necrosis factor-alpha and the expression of cyclooxygenase-2 in lipopolysaccharide-treated gravid human myometrial explants.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Cells, Cultured; Cyclooxygenase 2; Female; Humans; Hydroxyprogesterones; Lipopolysaccharides; Myometrium; Pregnancy; RNA, Messenger; Tumor Necrosis Factor-alpha | 2010 |
17-alpha-hydroprogesterone caproate and cervical changes.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Cervix Uteri; Female; Humans; Hydroxyprogesterones; Patient Selection; Pregnancy; Premature Birth; Progestins | 2010 |
Impact of 17P usage on NICU admissions in a managed medicaid population--a five-year review.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Chi-Square Distribution; Female; Gestational Age; Humans; Hydroxyprogesterones; Infant, Newborn; Infant, Premature; Injections, Intramuscular; Longitudinal Studies; Managed Care Programs; Medicaid; Multicenter Studies as Topic; National Institute of Child Health and Human Development (U.S.); Patient Compliance; Pregnancy; Premature Birth; Randomized Controlled Trials as Topic; Risk Factors; United States; United States Food and Drug Administration | 2010 |
Intramuscular 17α-hydroxyprogesterone caproate administration attenuates immunoresponsiveness of maternal peripheral blood mononuclear cells.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Female; Gestational Age; Humans; Hydroxyprogesterones; Immunomodulation; Immunosuppression Therapy; In Vitro Techniques; Injections, Intramuscular; Interleukin-6; Leukocytes, Mononuclear; Pregnancy; Premature Birth; Reference Values | 2010 |
17-hydroxyprogesterone caproate, progesterone, preterm birth prevention, and safety: who decides? Someone should.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Decision Support Techniques; Female; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth; Progesterone | 2011 |
The effect of 17α-hydroxyprogesterone caproate on preterm birth in women with an ultrasound-indicated cerclage.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cerclage, Cervical; Cervix Uteri; Female; Gestational Age; Humans; Hydroxyprogesterones; Kaplan-Meier Estimate; Pregnancy; Premature Birth; Progestins; Retrospective Studies; Secondary Prevention; Ultrasonography; Uterine Cervical Incompetence | 2011 |
Unintended consequences--the cost of preventing preterm births after FDA approval of a branded version of 17OHP.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Drug Approval; Drug Compounding; Drug Costs; Female; Health Care Costs; Humans; Hydroxyprogesterones; Obstetric Labor, Premature; Patents as Topic; Pregnancy; Premature Birth; United States; United States Food and Drug Administration | 2011 |
Deus ex Makena?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Female; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth; Progesterone; Progestins | 2011 |
Unjustified increase in cost of care resulting from U.S. Food and Drug Administration approval of Makena (17α-hydroxyprogesterone caproate).
Topics: 17 alpha-Hydroxyprogesterone Caproate; Drug Approval; Drug Compounding; Female; Health Care Costs; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth; United States; United States Food and Drug Administration | 2011 |
Trends in prematurity: what do changes at an urban institution suggest about the public health impact of 17-alpha hydroxyprogesterone caproate?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cross-Sectional Studies; Delivery, Obstetric; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gestational Age; Humans; Hydroxyprogesterones; Infant; Infant, Newborn; Infant, Premature; Logistic Models; Male; Pregnancy; Premature Birth; Progestins; Public Health; Secondary Prevention; Urban Population | 2012 |
Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Half-Life; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy, Triplet; Pregnancy, Twin; Premature Birth; Progestins; Randomized Controlled Trials as Topic | 2011 |
The rates of abnormal glucose challenge tests and gestational diabetes in women receiving 17α-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Blood Glucose; Diabetes, Gestational; Dose-Response Relationship, Drug; Female; Glucose Intolerance; Glucose Tolerance Test; Humans; Hydroxyprogesterones; Logistic Models; Obesity; Pregnancy; Premature Birth; Progestins; Prospective Studies; Secondary Prevention; Young Adult | 2011 |
The influence of prior obstetrical history on current 17-hydroxyprogesterone caproate use.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Gestational Age; Humans; Hydroxyprogesterones; Patient Acceptance of Health Care; Practice Patterns, Physicians'; Pregnancy; Pregnancy, High-Risk; Premature Birth; Progestins; Retrospective Studies; Secondary Prevention; Term Birth; Treatment Refusal; Young Adult | 2011 |
Recurrent preterm birth in women treated with 17 α-hydroxyprogesterone caproate: the contribution of risk factors in the penultimate pregnancy.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Fetal Membranes, Premature Rupture; Humans; Hydroxyprogesterones; Logistic Models; Pregnancy; Premature Birth; Progestins; Retrospective Studies; Risk Factors; Secondary Prevention; Treatment Outcome; United States | 2012 |
17-alphahydroxyprogesterone caproate in women with previous spontaneous preterm delivery: does a previous term delivery affect the rate of recurrence?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Infant, Premature; Pregnancy; Premature Birth; Progestins; Retrospective Studies; Risk; Secondary Prevention; Term Birth | 2011 |
Influence of gestational age and reason for prior preterm birth on rates of recurrent preterm delivery.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Age Factors; Female; Fetal Membranes, Premature Rupture; Gestational Age; Humans; Hydroxyprogesterones; Infant, Newborn; Infant, Premature; Pregnancy; Premature Birth; Progestins; Secondary Prevention | 2011 |
Metabolism of 17-alpha-hydroxyprogesterone caproate by human placental mitochondria.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Mitochondria; Placenta; Pregnancy | 2012 |
17-α hydroxyprogesterone caproate for the prevention of preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hydroxyprogesterones; Obstetric Labor, Premature; Pregnancy; Pregnancy Outcome; Pregnancy, High-Risk; Premature Birth; Prenatal Care; United States; United States Food and Drug Administration; Women's Health | 2012 |
Iatrogenic autoimmune progesterone dermatitis caused by 17alpha-hydroxyprogesterone caproate for preterm labor prevention.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Autoimmune Diseases; Dermatitis; Female; Fluorescent Antibody Technique, Indirect; Humans; Hydroxyprogesterones; Iatrogenic Disease; Obstetric Labor, Premature; Pregnancy; Progesterone; Progestins | 2011 |
Quality investigation of hydroxyprogesterone caproate active pharmaceutical ingredient and injection.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Drug Approval; Drug Compounding; Female; Humans; Hydroxyprogesterones; Injections; Pregnancy; Premature Birth; Progestins; Quality Control; United States; United States Food and Drug Administration | 2012 |
Pregnancy outcomes of managed Medicaid members prescribed home administration of 17 α-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adolescent; Adult; Female; Gestational Age; Guideline Adherence; Home Care Services; Humans; Hydroxyprogesterones; Infant, Newborn; Infant, Premature; Medicaid; Medication Adherence; Practice Guidelines as Topic; Pregnancy; Pregnancy Outcome; Premature Birth; Progestins; Retrospective Studies; United States | 2012 |
Studies examine fetal surgery trade-offs, drug interactions, and uterine rupture.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Child Development; Drug Interactions; Dystocia; Female; Fetal Diseases; Humans; Hydroxyprogesterones; Infant; Infant, Newborn; Meningomyelocele; Pregnancy; Pregnancy Complications; Premature Birth; Prenatal Diagnosis; Progestins; Risk; Uterine Rupture; Vaginal Birth after Cesarean | 2012 |
Multigeneration reproductive study of hydroxyprogesterone caproate (HPC) in the rat: laboratory results and clinical significance.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Animals; Breeding; Female; Half-Life; Hydroxyprogesterones; Male; Models, Animal; No-Observed-Adverse-Effect Level; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Sprague-Dawley; Reproduction; Toxicity Tests | 2012 |
Pregnancy outcomes of women receiving compounded 17 α-hydroxyprogesterone caproate for prophylactic prevention of preterm birth 2004 to 2011.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Drug Packaging; Female; Fetal Death; Home Care Services; Humans; Hydroxyprogesterones; Infant Mortality; Infant, Newborn; Pregnancy; Pregnancy Outcome; Premature Birth; Progestins | 2012 |
The prediction of recurrent preterm birth in patients on 17-alpha-hydroxyprogesterone caproate using serial fetal fibronectin and cervical length.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Biomarkers; Cervical Length Measurement; Cohort Studies; Decision Support Techniques; Female; Fibronectins; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth; Progestins; Recurrence; Regression Analysis; Retrospective Studies; Sensitivity and Specificity | 2012 |
Cerclage for the prevention of preterm birth in high risk women receiving intramuscular 17-α-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cerclage, Cervical; Combined Modality Therapy; Estrogen Antagonists; Female; Humans; Hydroxyprogesterones; Injections, Intramuscular; Multicenter Studies as Topic; Pregnancy; Pregnancy, High-Risk; Premature Birth; Randomized Controlled Trials as Topic; Retrospective Studies; Uterine Cervical Incompetence; Young Adult | 2012 |
Rates of recurrent preterm birth by maternal body habitus in women receiving 17α-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Body Mass Index; Cohort Studies; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Obesity; Pregnancy; Pregnancy Complications; Premature Birth; Progesterone Congeners; Recurrence; Retrospective Studies; Young Adult | 2013 |
Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adrenal Glands; Animals; Aryldialkylphosphatase; ATP-Binding Cassette Transporters; Carboxylesterase; Cholestasis; Cotinine; Cytochrome P-450 Enzyme System; Estradiol; Estrogen Receptor alpha; Estrogens; Ethinyl Estradiol; Female; Fetus; Gene Expression Regulation, Developmental; Glucuronosyltransferase; Hepatocytes; Humans; Hydroxyprogesterones; Intestine, Small; Kidney; Liver; Lung; Male; Maternal Behavior; Membrane Transport Proteins; Minor Histocompatibility Antigens; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Pesticides; Placenta; Pregnancy; Progesterone; Retinoic Acid 4-Hydroxylase; RNA, Messenger; Smoking; Taurocholic Acid | 2013 |
Effectiveness of 17-α-hydroxyprogesterone caproate on preterm birth prevention in women with history-indicated cerclage.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Birth Weight; Cerclage, Cervical; Cervical Length Measurement; Female; Gestational Age; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth; Progestins; Retrospective Studies; Time Factors; Uterine Cervical Incompetence | 2013 |
Progesterone and preterm delivery--deja vu all over again.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Obstetric Labor, Premature; Pregnancy; Progesterone Congeners; Risk | 2003 |
Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Castor Oil; Female; Humans; Hydroxyprogesterones; Injections; Labor, Induced; Obstetric Labor, Premature; Pregnancy | 2003 |
The use of a new long-acting progestational compound (17-alpha-hydroxyprogesterone-capronate) in infertility and habitual abortion.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Abortion, Habitual; Abortion, Induced; Female; Humans; Hydroxyprogesterones; Infertility; Infertility, Female; Pregnancy; Progesterone; Progestins | 1956 |
[Research on the maintenance of pregnancy by 17 alpha-hydroxyprogesterone caproate in the castrated pregnant rabbit].
Topics: 17 alpha-Hydroxyprogesterone Caproate; Animals; Castration; Female; Humans; Hydroxyprogesterones; Maintenance; Male; Orchiectomy; Pregnancy; Progesterone; Rabbits; Research | 1958 |
Attempts to induce and maintain pregnancy in prepuberal mice following treatment with 17 alpha-hydroxyprogesterone 17-n-caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Animals; Caproates; Hydroxyprogesterones; Mice; Pregnancy; Progesterone; Reproduction | 1958 |
Clinical use of 17 alpha-hydroxyprogesterone 17-n-caproate in habitual abortion.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Abortion, Habitual; Abortion, Induced; Caproates; Female; Humans; Hydroxyprogesterones; Pregnancy; Progesterone | 1958 |
Clinical use of 17 alpha-hydroxyprogesterone 17-n-caproate in the prevention of premature labor, and its effect upon fetal salvage.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Caproates; Female; Fetus; Humans; Hydroxyprogesterones; Labor, Obstetric; Obstetric Labor, Premature; Pregnancy; Progesterone | 1958 |
Treatment of human diabetic pregnancies with estradiol valerate and 17 alpha-hydroxyprogesterone 17-n-caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Caproates; Diabetes Mellitus; Estradiol; Female; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy in Diabetics; Progesterone | 1958 |
Metabolism of 17 alpha-hydroxyprogesterone-4-C14-17 alpha-caproate by homogenates of rat liver and human placenta.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Caproates; Female; Humans; Hydroxyprogesterones; Liver; Placenta; Pregnancy; Progesterone | 1961 |
[Corpus luteum hormone in threatened abortion with special reference to therapy with hydroxy-progesterone-capronate (proluton depot). (Electromyography and Prof. Ashitaka's urine reactions)].
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abortion, Induced; Abortion, Threatened; Corpus Luteum Hormones; Electromyography; Female; Humans; Hydroxyprogesterones; Pregnancy; Progesterone | 1959 |
The use of 17-alpha-hydroxyprogesterone caproate to maintain pregnancy.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Abortion, Induced; Abortion, Spontaneous; Caproates; Female; Humans; Hydroxyprogesterones; Pregnancy; Progestins | 1962 |
Double-blind study of effect of 17-hydroxyprogesterone caproate on abortion rate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; Abortion, Habitual; Abortion, Induced; Abortion, Spontaneous; Caproates; Double-Blind Method; Female; Humans; Hydroxyprogesterones; Pregnancy | 1963 |
[FEMALE PSEUDOHERMAPHRODITISM PROBABLY INDUCED BY A PROGESTINIC ADMINISTERED INTRAMUSCULARLY: 17-ALPHA-HYDROXYPROGESTERONE CAPRONATE].
Topics: 17 alpha-Hydroxyprogesterone Caproate; 17-alpha-Hydroxyprogesterone; 46, XX Disorders of Sex Development; Abnormalities, Drug-Induced; Abortion, Threatened; Disorders of Sex Development; Female; Humans; Hydroxyprogesterones; Infant; Infant, Newborn; Pregnancy; Progestins; Toxicology | 1964 |
ACOG Committee Opinion. Use of progesterone to reduce preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Obstetric Labor, Premature; Pregnancy | 2003 |
[Can progesterone prevent premature birth?].
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Obstetric Labor, Premature; Pregnancy | 2004 |
Impairment of male reproduction in adult rats exposed to hydroxyprogesterone caproate in utero.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Animals; Embryonic and Fetal Development; Epididymis; Female; Hydroxyprogesterones; Infertility, Male; Male; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Sperm Count; Sperm Motility | 2004 |
Transient parkinsonism: induced by progesterone or pregnancy?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abortion, Threatened; Adult; Brain Ischemia; Delayed-Action Preparations; Dilatation and Curettage; Dominance, Cerebral; Female; Follow-Up Studies; Frontal Lobe; Humans; Hydroxyprogesterones; Magnetic Resonance Imaging; Parkinsonian Disorders; Pregnancy; Pregnancy Complications; Remission, Spontaneous; Tocolytic Agents; Tomography, Emission-Computed, Single-Photon | 2004 |
Functional effects of 17alpha-hydroxyprogesterone caproate (17P) on human myometrial contractility in vitro.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Biopsy; Cesarean Section; Female; Humans; Hydroxyprogesterones; Hysterectomy; In Vitro Techniques; Isometric Contraction; Myometrium; Oxytocin; Phenylephrine; Pregnancy; Uterine Contraction | 2004 |
Gestational exposure to hydroxyprogesterone caproate suppresses reproductive potential in male rats.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Animals; Copulation; Embryo Implantation; Female; Fetal Resorption; Hydroxyprogesterones; Male; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Wistar; Reproduction; Sex Ratio | 2005 |
Does progesterone treatment influence risk factors for recurrent preterm delivery?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Humans; Hydroxyprogesterones; Multivariate Analysis; Obstetric Labor, Premature; Pregnancy; Progestins; Recurrence; Risk Factors | 2005 |
17 alpha-hydroxyprogesterone caproate (17P) usage in a Medicaid managed care plan and reduction in neonatal intensive care unit days.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Intensive Care Units, Neonatal; Managed Care Programs; Medicaid; Pregnancy; United States | 2005 |
Hydroxyprogesterone caproate and progesterone increase tumor necrosis factor-alpha production in lipopolysaccharide stimulated whole blood from non-pregnant women.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Humans; Hydroxyprogesterones; In Vitro Techniques; Lipopolysaccharides; Pregnancy; Premature Birth; Progesterone; Tumor Necrosis Factor-alpha | 2005 |
17-Hydroxyprogesterone caproate reverses induced vasoconstriction of the fetoplacental arteries by the thromboxane mimetic U46619.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; 17 alpha-Hydroxyprogesterone Caproate; Angiotensin II; Cytokines; Female; Fetus; Humans; Hydroxyprogesterones; Placenta; Pregnancy; Vasoconstriction | 2006 |
17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Cost-Benefit Analysis; Decision Support Techniques; Female; Gestational Age; Health Care Costs; Hospitalization; Humans; Hydroxyprogesterones; Multivariate Analysis; Obstetric Labor Complications; Obstetric Labor, Premature; Parity; Pregnancy; Premature Birth; Progestins; Risk Factors; Secondary Prevention; United States | 2006 |
The use of progestational agents for preterm birth: lessons from a mouse model.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Animals; C-Reactive Protein; Female; Hydroxyprogesterones; Interleukin-10; Interleukin-6; Lipopolysaccharides; Medroxyprogesterone Acetate; Mice; Models, Animal; Pregnancy; Premature Birth; Progestins | 2006 |
Population-based case-control teratogenic study of hydroxyprogesterone treatment during pregnancy.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abnormalities, Drug-Induced; Abnormalities, Multiple; Adult; Case-Control Studies; Female; Gestational Age; Humans; Hungary; Hydroxyprogesterones; Infant, Newborn; Male; Pregnancy; Registries; Retrospective Studies; Risk Factors; Teratogens | 2006 |
Massive pre-placental and subchorionic haematoma.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Fetal Membranes, Premature Rupture; Hematoma; Humans; Hydroxyprogesterones; Nifedipine; Placenta Diseases; Pregnancy; Pregnancy Outcome; Progestins; Thrombosis; Tocolytic Agents; Ultrasonography; Uterine Hemorrhage | 2006 |
17 Progesterone for preterm birth prevention: a potential 2 billion dollar opportunity.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Costs and Cost Analysis; Female; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth | 2007 |
Increased recurrence of preterm delivery with early cessation of 17-alpha-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abortion, Habitual; Adult; Female; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy Trimester, First; Pregnancy Trimester, Second; Premature Birth; Retrospective Studies | 2007 |
Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cerclage, Cervical; Female; Gestational Age; Humans; Hydroxyprogesterones; Pregnancy; Premature Birth; Progesterone Congeners; Retrospective Studies; Secondary Prevention | 2007 |
Reducing preterm births.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Multicenter Studies as Topic; Pregnancy; Premature Birth; Progestins; Randomized Controlled Trials as Topic | 2007 |
Progesterone and preterm labor--still no definite answers.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Intravaginal; Cervix Uteri; Female; Humans; Hydroxyprogesterones; Obstetric Labor, Premature; Pregnancy; Pregnancy Outcome; Pregnancy, Multiple; Premature Birth; Progesterone; Twins | 2007 |
Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter?
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adolescent; Adult; Female; Gestational Age; Humans; Hydroxyprogesterones; Obstetric Labor, Premature; Pregnancy; Premature Birth; Recurrence; Retrospective Studies; Tocolytic Agents; Treatment Outcome | 2007 |
Clinical characteristics of women prescribed 17 alpha-hydroxyprogesterone caproate in the community setting.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Female; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy Outcome; Premature Birth; Recurrence; Residence Characteristics; Retrospective Studies; Tocolytic Agents | 2007 |
Gestiva for preventing prematurity: a new view of an old therapy.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Pregnancy; Premature Birth; Progestins | 2007 |
The effect of esterases on 17alpha-hydroxyprogesterone caproate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Chromatography, High Pressure Liquid; Esterases; Female; Gestational Age; Humans; Hydroxyprogesterones; In Vitro Techniques; Liver; Obstetric Labor, Premature; Placenta; Pregnancy | 2008 |
Progesterone and preterm birth.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Cervix Uteri; Female; Gestational Age; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy, Multiple; Premature Birth; Progesterone; Research Design; Risk Factors; Twins; Ultrasonography | 2007 |
Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Cell Line, Tumor; Female; Gene Expression; Humans; Hydroxyprogesterones; Pregnancy; Progesterone; Progestins; Receptors, Glucocorticoid; Receptors, Progesterone | 2007 |
The use of 17 alpha-hydroxyprogesterone caproate (17p) in women with cervical cerclage.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Cerclage, Cervical; Cohort Studies; Estrogen Antagonists; Female; Gestational Age; Humans; Hydroxyprogesterones; Nursing Care; Obstetric Labor, Premature; Pregnancy; Pregnancy Outcome; Retrospective Studies | 2008 |
Hormone load tests in the first half of pregnancy--a diagnostic and therapeutic approach.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abortion, Spontaneous; Abortion, Threatened; Allylestrenol; Betamethasone; Chorionic Gonadotropin; Chorionic Gonadotropin, beta Subunit, Human; Dehydroepiandrosterone; Endocrine Glands; Estradiol; Female; Hormones; Humans; Hydroxyprogesterones; Peptide Fragments; Pregnancy; Pregnancy Trimester, First; Pregnancy Trimester, Second; Progesterone; Promegestone; Tamoxifen | 1984 |
On reducing prematurity: the hospital's role.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adrenergic beta-Agonists; Female; Hospital Departments; Humans; Hydroxyprogesterones; Indomethacin; Obstetric Labor, Premature; Obstetrics and Gynecology Department, Hospital; Patient Education as Topic; Pregnancy; Prospective Studies; Risk | 1982 |
Evaluation of the use of Proluton-Depot (hydroxyprogesterone hexanoate) in early pregnancy.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Corpus Luteum Maintenance; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Infertility, Female; Outcome and Process Assessment, Health Care; Pregnancy; Prenatal Exposure Delayed Effects | 1982 |
Transplacental carcinogenesis (adrenocortical carcinoma) associated with hydroxyprogesterone hexanoate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adrenal Cortex Neoplasms; Female; Humans; Hydroxyprogesterones; Infant; Maternal-Fetal Exchange; Pregnancy; Prenatal Exposure Delayed Effects | 1983 |
Effects of prenatally administered 17 alpha-hydroxyprogesterone caproate on adolescent males.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adolescent; Aggression; Female; Gender Identity; Gestational Age; Humans; Hydroxyprogesterones; Identification, Psychological; Leisure Activities; Male; Pregnancy; Prenatal Exposure Delayed Effects; Reading; Social Conformity; Space Perception; Television | 1984 |
Evaluation of the teratogenic potential of delalutin (17 alpha-hydroxyprogesterone caproate) in mice.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abnormalities, Drug-Induced; Animals; Body Weight; Dose-Response Relationship, Drug; Female; Fetal Resorption; Hydroxyprogesterones; Muridae; Pregnancy; Progestins; Sex Factors; Tretinoin | 1983 |
[Usefulness of cytohormonal vaginal smears for monitoring threatened early pregnancy].
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abortion, Threatened; Adult; False Positive Reactions; Female; Fetal Monitoring; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy Trimester, First; Vaginal Smears | 1982 |
Pregnancy maintenance after early luteectomy by 17-hydroxyprogesterone-capronate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abortion, Spontaneous; Adult; Corpus Luteum; Estradiol; Female; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy Trimester, First; Progesterone | 1982 |
[Single administration of a progesterone preparation during early gravidity of gilts following synchronized ovulation and induction of puberty to lower the age of first insemination].
Topics: 17 alpha-Hydroxyprogesterone Caproate; Animals; Estrus Synchronization; Female; Hydroxyprogesterones; Insemination; Litter Size; Ovulation Induction; Pregnancy; Pregnancy, Animal; Swine | 1981 |
[Effect of a single application of progesterone during early pregnancy on the fertility of gilts of different live weights].
Topics: 17 alpha-Hydroxyprogesterone Caproate; Animals; Body Weight; Delayed-Action Preparations; Female; Fertility; Hydroxyprogesterones; Injections, Intramuscular; Litter Size; Pregnancy; Swine | 1981 |
Suppression of threatened premature labor by administration of cortisol and 17 alpha-hydroxyprogesterone caproate: a comparison with ritodrine.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Estradiol; Estriol; Estrogen Antagonists; Female; Humans; Hydrocortisone; Hydroxyprogesterones; Obstetric Labor, Premature; Pregnancy; Progesterone; Propanolamines; Ritodrine; Testosterone | 1980 |
Preferential expression of long form prolactin receptor mRNA in the rat brain during the oestrous cycle, pregnancy and lactation: hormones involved in its gene expression.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Animals; Base Sequence; Blotting, Southern; Brain; DNA Primers; Estradiol; Estrus; Female; Gene Expression; Growth Hormone; Hydroxyprogesterones; Hypophysectomy; Lactation; Molecular Sequence Data; Oligonucleotide Probes; Ovariectomy; Polymerase Chain Reaction; Pregnancy; Pregnancy, Animal; Progesterone Congeners; Prolactin; Rats; Rats, Sprague-Dawley; Receptors, Prolactin; RNA, Messenger | 1994 |
Failure of hydroxyprogesterone caproate to maintain pregnancy in ovariectomised mares.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abortion, Veterinary; Animals; Estrogen Antagonists; Female; Horse Diseases; Horses; Hydroxyprogesterones; Ovariectomy; Pregnancy; Progesterone Congeners | 1993 |
The origin of spermatozoa does not affect intracytoplasmic sperm injection outcome.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Ejaculation; Embryo Implantation; Embryo Transfer; Female; Humans; Hydroxyprogesterones; Infertility, Male; Male; Oligospermia; Pregnancy; Specimen Handling; Sperm Injections, Intracytoplasmic; Spermatozoa; Testis; Treatment Outcome | 2001 |
Organ preserving method in the management of atypical endometrial hyperplasia.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Oral; Adult; Endometrial Hyperplasia; Female; Humans; Hydroxyprogesterones; Injections, Intramuscular; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Pregnancy; Progesterone Congeners | 2001 |
Preliminary experience with steroidal ovarian suppression for prevention of severe ovarian hyperstimulation syndrome in IVF patients.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Chorionic Gonadotropin; Embryo Transfer; Estradiol; Female; Fertilization in Vitro; Humans; Hydroxyprogesterones; Infertility, Female; Injections, Intramuscular; Ovarian Hyperstimulation Syndrome; Ovary; Polycystic Ovary Syndrome; Pregnancy; Progesterone; Risk Factors | 2001 |
[Are gestagens suitable for lowering the membrane potential of the uterine muscle and eliminating the need for beta-mimetics?].
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adrenergic beta-Agonists; Female; Humans; Hydroxyprogesterones; Infant, Newborn; Membrane Potentials; Myometrium; Pregnancy; Progesterone Congeners; Tocolysis; Uterine Contraction | 1992 |
[Regularities and paradoxes of endocrine dependence and hormonal therapy of endometrial cancer].
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adenocarcinoma; Adult; Delayed-Action Preparations; Estrogen Antagonists; Female; Humans; Hydroxyprogesterones; Middle Aged; Pregnancy; Pregnancy Complications, Neoplastic; Progesterone Congeners; Tamoxifen; Uterine Neoplasms | 1990 |
Ovum donation by sisters in ovarian failure: simplified priming and early withdrawal of exogenous support.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Adult; Embryo Transfer; Estradiol; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Humans; Hydroxyprogesterones; Leuprolide; Menopause; Menopause, Premature; Menstrual Cycle; Ovarian Follicle; Pregnancy; Progesterone; Tissue Donors | 1989 |
Ovarian tumors in pregnancy.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abortion, Spontaneous; Adult; Combined Modality Therapy; Female; Humans; Hydroxyprogesterones; Medroxyprogesterone; Medroxyprogesterone Acetate; Ovarian Neoplasms; Ovariectomy; Pregnancy; Pregnancy Complications, Neoplastic | 1988 |
First trimester bleeding in clinical IVF pregnancies.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Chorionic Gonadotropin; Delayed-Action Preparations; Embryo Transfer; Female; Fertilization in Vitro; Humans; Hydroxyprogesterones; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Trimester, First; Progesterone; Progesterone Congeners; Risk Factors; Uterine Hemorrhage | 1988 |
Embryotoxicity of sex steroidal hormones in nonhuman primates: II. Hydroxyprogesterone caproate, estradiol valerate.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abnormalities, Drug-Induced; Abortion, Veterinary; Animals; Drug Combinations; Estradiol; Female; Fetal Death; Fetal Resorption; Gestational Age; Hydroxyprogesterones; Macaca fascicularis; Macaca mulatta; Maternal-Fetal Exchange; Pregnancy | 1987 |
Estrogen and progesterone receptors in the organs of prenatal cynomolgus monkey and laboratory mouse.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Animals; Ethinyl Estradiol; Female; Fetus; Hydroxyprogesterones; Macaca; Macaca fascicularis; Mice; Microchemistry; Myocardium; Pregnancy; Pregnenediones; Progesterone; Receptors, Estrogen; Receptors, Progesterone; Tissue Distribution; Uterus | 1986 |
Prevention of pre-term labour with progesterone.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Female; Humans; Hydroxyprogesterones; Obstetric Labor, Premature; Pregnancy; Risk | 1986 |
Congenital malformations among offspring exposed in utero to progestins, Olmsted County, Minnesota, 1936-1974.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abnormalities, Drug-Induced; Ethisterone; Female; Fetal Death; Humans; Hydroxyprogesterones; Infant, Newborn; Male; Maternal-Fetal Exchange; Medroxyprogesterone; Minnesota; Norethindrone; Pregnancy; Prenatal Exposure Delayed Effects; Progesterone; Progestins | 1985 |
Calmodulin concentration in the uterus during pregnancy and influence of sex steroids.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Animals; Calmodulin; Estriol; Female; Gonadal Steroid Hormones; Humans; Hydroxyprogesterones; Labor, Obstetric; Pregnancy; Pregnancy, Animal; Rats; Rats, Inbred Strains; Uterus | 1985 |